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University of Pittsburgh, 2009
 
Interleukin-17 (IL-17) is a cytokine produced mainly by T cell lineages that plays a key 
role in regulation of neutrophil responses.  Given the importance of neutrophils in the immune 
response directed against extracellular pathogens, it is no surprise that IL-17 is important in host 
defense against a multitude of pathogens.  Importantly, however, neutrophils also have been 
shown to play a role in several immunopathological conditions, including acute lung injury.  In 
this dissertation, we evaluate the role that IL-17 plays in the immunopathology of influenza 
infection.  We show here that IL-17 is produced as early as day 2 following influenza challenge, 
and that this expression is sustained throughout the first week of infection.  Further, we identify 
γδ T cells as at least one important source of IL-17 in response to influenza.  We also 
demonstrate that loss of IL-17 receptor A (IL-17RA) signaling results in a profound decrease in 
neutrophil recruitment to the lung following influenza challenge.  This decrease in neutrophils 
results in substantially less inflammation and lung injury, as well as higher survival rates.  
Additionally, there is only a moderate impact on viral clearance and T cell responses.  Further, 
we detail similar findings in a non-infectious aspiration model of acute lung injury.  Taken 
together, this data suggests that IL-17 signaling may be a key event, and intriguing therapeutic 
target, in the pathogenesis of acute lung injury. 
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1. Introduction 
 
 
1.1 Acute Lung Injury and Acute Respiratory Distress Syndrome 
 
1.1.1 Definition and Epidemiology 
 
Acute lung injury (ALI) is a syndrome characterized by increased vascular permeability resulting 
in persistent lung inflammation, and can afflict people of all ages.  The term ALI covers a 
spectrum of severity, with the most severe injury being referred to as acute respiratory distress 
syndrome (ARDS).  A diagnosis of ALI is determined by four clinical features: acute onset, 
bilateral infiltrates, hypoxemia (PaO2/FiO2 ratio between 201 and 300 mmHg), and no evidence 
of an elevated left atrial pressure (to distinguish it from cardiogenic pulmonary edema).  ARDS 
is distinguished from ALI by a more severe hypoxemia (PaO2/FiO2 ratio < 200 mmHg), but 
otherwise shares the same definition (1, 2). 
ALI is a significant burden on the healthcare system.  One multi-center cohort study of 
1131 patients demonstrated that the incidence and mortality of ALI increases with age.  
Extrapolating that data, it is estimated that there are roughly 190,600 cases of ALI in the United 
States each year with nearly a 40% mortality rate, meaning 74,500 patients die of ALI each year 
in this country (3).  Other studies have suggested that 10-15% of patients admitted to intensive 
care units meet the diagnostic criteria of ALI, and that this number increases to 20%  when 
looking only at patients on mechanical ventilation (4-7). 
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ALI can be precipitated by a number of causes.  Although more than 60 causes have been 
identified, the majority of cases of ALI are due to a much shorter list of causes, both pulmonary 
and extrapulmonary (7, 8).  The most common cause is sepsis (8-10), and the risk of ARDS may 
be especially elevated in septic patients with a history of alcohol abuse (11, 12).  In one study of 
220 patients with septic shock, 70% of the patients with a history of alcohol abuse developed 
ARDS while 31% of the septic patients who were non-alcoholics developed ARDS (13). 
Infectious pneumonias are another major cause of ALI.  Among the most common 
pathogens are Streptococcus pneumoniae, Legionella pneumophila, Staphylococcus aureus, 
enteric gram negative organisms, and respiratory viruses such as influenza.  While community-
acquired pneumonias are very common (in fact, pneumonia is the most common cause of ARDS 
that arises outside of the hospital), it is also important to note that nosocomial pneumonias, 
including those caused by Pseudomonas aeruginosa can progress to ARDS as well (14, 15). 
Yet another common cause of ALI is the aspiration of stomach contents.  It has been 
estimated that as many as 33% of patients who suffer a gastric aspiration develop severe lung 
injury (9, 16).  This may also be seen in patients who develop a tracheoesphageal fistula.  Gastric 
contents can be damaging in several ways.  The pH of the stomach acid may contribute to injury, 
but gastric enzymes and small food particles may also play a role (17). 
Other common causes of ALI include severe trauma or burns (18), massive blood 
transfusions (8), drugs (including aspirin, cocaine, opioids, phenothiazines, and some 
chemotherapeutic agents) (19, 20), fat or air emboli in the pulmonary vascular bed (21, 22), and 
graft failure following lung or bone marrow transplant (23-25). 
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1.1.2 Respiratory viral infections and ALI 
 
As mentioned previously, infectious pneumonias are among the most common causes of ALI.  
Of particular interest is the role of ALI in the pathogenesis of respiratory viral infections.  In 
2003, an outbreak of a novel respiratory coronavirus, the severe acute respiratory syndrome 
(SARS) virus, began in Asia and rapidly spread as far as Canada.  Within six months of the index 
case, over 8,000 cases had been documented worldwide, the majority of which were in China.  
Among patients with SARS, nearly 25% progressed and developed severe respiratory failure.  
One study of 199 SARS patients reported a mortality rate at 4 weeks post-infection of 10%, but 
that jumped to 52% at 13 weeks when looking specifically patients who were admitted to an 
intensive care unit.  Of those who died in the ICU, 80% had a proximate cause of death given as 
ARDS or complications related to ARDS (26). 
Even more recently, cases of avian influenza A (H5N1) have been documented among 
humans.  Between December, 2003 and August, 2005, 112 cases of H5N1 influenza were 
documented in southeastern Asia, mostly among poultry workers or their contacts (27).  While 
human-to-human spread has been documented, it is highly inefficient, which explains the low 
infection rate (28).  However, manifestations of ARDS are common, with rates of respiratory 
failure ranging from 70-100% (28-31).  This is also reflected in the high mortality rates.  
Morality tends to peak on an average of 9-10 days after onset of illness with progressive 
respiratory failure being the cause of death (28-31). 
Historically, influenza pandemics have been even more severe.  Perhaps the worst was 
the 1918 “Spanish” Influenza A (H1N1) pandemic which killed nearly 50 million people 
worldwide (32).  While our insights are limited due to the lack of tissue, pathologists at the time 
 3 
described severe destruction of the lung tissue and noted that this was unlike what was normally 
seen in more typical pneumonias (33, 34).  Further, researchers have recently been able to use 
plasmid-based reverse genetics to reconstruct the 1918 influenza strain and study it in animal 
models (35).  Non-human primates infected with the 1918 influenza demonstrated severe 
alveolar damage, extensive pulmonary edema, and hemorrhagic exudates consistent with 
findings associated with ARDS (36, 37).  Mouse models of the 1918 influenza virus also confirm 
the severe lung pathology described in human patients (38, 39).  Given influenza’s ability to 
rapidly mutate (discussed later), it is reasonable to believe that a similar pandemic, perhaps even 
stemming from current circulating H5N1 strains, may strike again.  For that reason, it is 
important to understand the mechanisms by which ALI and ARDS develop in response to viral 
infections. 
 
1.1.3  Molecular and Cellular Mechanisms of ALI 
 
Regardless of the cause, much of the molecular and cellular pathology observed in ALI is the 
same.  There is generally damage to the alveolar epithelium, edema formation, an accumulation 
of inflammatory cells (especially neutrophils), and a strong increase in proinflammatory 
cytokines, including tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-6, and IL-8.  
The inflammation results in worsening edema, resulting in hemorrhagic, proteinaceous fluid 
filling the air spaces (40-45). 
Of the two separate barriers that make up the alveolar-capillary barrier- the vascular 
endothelial cells and the alveolar epithelium- the alveolar epithelium is much less permeable.  
Therefore, loss of epithelial integrity is a key component to alveolar flooding (46).  The 
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epithelium is made up of two cell types.  Type I cells are squamous and comprise approximately 
90% of the alveolar surface area.  Type II cells are cuboidal, and while they make up only 10% 
of the surface area, they are functionally very important, as they are a major source of surfactant 
production and ion transport.  Subsequently, loss of type II alveolar cells may impair removal of 
edema fluid by affecting epithelial fluid transport, as well as reducing the production of 
surfactant (40, 47-49).  Importantly, in the case of infectious pneumonias, the alveolar epithelium 
also serves to limit spread of the infectious organism to the bloodstream.  Therefore, damage to 
the epithelium may lead to septic shock in these cases (50). 
The production of proinflammatory cytokines by epithelial cells, fibroblasts, and 
inflammatory cells may contribute to the worsening immunopathology observed in ALI.  In 
particular, production of IL-8 by fibroblasts and alveolar macrophages serve to recruit large 
numbers of neutrophils (51, 52).  Additionally, IL-1β, TNF-α, CXCL2 (macrophage 
inflammatory protein, or MIP-2), and multiple other chemokines are produced by resident 
pulmonary cell populations (44, 53).  However, it is also important to note that in addition to the 
production of proinflammatory cytokines, one must also consider the balance between 
proinflammatory cytokines and the production of anti-inflammatory cytokines such as IL-10 and 
endogenous anti-inflammatory mediators, including IL-1 receptor antagonist (IL-1RA), soluble 
TNF-α receptor, and autoantibodies against IL-8 (54). 
The neutrophils that are recruited to the lung by production of these proinflammatory 
cytokines and chemokines have been implicated as a major player in ALI (40, 51).  In fact, 
neutrophils are the dominant cell found in the edema fluid and bronchoalveolar lavage fluid 
(BALF) in ALI patients (54, 55).  The neutrophils serve as another major source for cytokines 
and chemokines, especially IL−1β, TNF-α, CXCL1 (KC) and CXCL2 (MIP-2).   
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Further, neutrophils are a source of reactive oxygen intermediates (ROI), which are 
capable of activating NF-κB and CREB, leading to even more production of proinflammatory 
cytokines (56, 57).  These ROI may also play a role in oxidative damage to the cells of the 
airway and the oxidation of phospholipids in the airway (58).  A recent study has demonstrated 
that oxidized phospholipids (OxPLs) are capable of serving as an endogenous signal for Toll-like 
Recepter (TLR)- 4.  This signaling is TRIF/TRAF6 dependent (MyD88-independent), and 
blocking this signaling lessens the degree of lung injury, suggesting another mechanism by 
which neutrophils could contribute to the immunopathology of acute lung injury.  These authors 
also reported that large concentrations of OxPLs are present in the lungs of all severe cases of 
lung injury that they examined, which included human cases of H5N1 influenza and SARS (59).  
Other studies have confirmed a role for TLR 4 signaling in ALI (60-62), as well as demonstrated 
a role TLR 2 signaling (60). 
Additionally, neutrophils are a source of proteases, including elastase, collagenase, and 
protease 3.  These proteases are beneficial and necessary in helping the neutrophil degrade 
extracellular matrices as they leave the vasculature and move through connective tissue to the 
site of infection.  However, in the context of ALI, the excessive neutrophil recruitment results in 
excessive production of proteases, which then in turn results in damage to the lungs’ connective 
tissue matrix (58, 63). 
Following this acute phase there is a resolution of lung injury.  In some patients, this is 
uncomplicated and rapid (64).  In other patients, there is progression to fibrosing alveolitis (41), 
which is marked by the accumulation of mesenchymal cells in the alveolar space (65), along with 
increased production of collagen and fibronectin (66).  Fibrosis results in an increased risk of 
death (67), and is thought to begin during the acute phase of lung injury, promoted by IL-1 (68).  
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1.1.4  Treatment of ALI and ARDS 
 
Managing a patient with severe lung injury first involves searching for the underlying cause, and 
in the case of treatable infections such as pneumonia or sepsis, treatment with the appropriate 
antimicrobial agents (69, 70).  Beyond that, no specific therapies exist for the treatment of ALI.  
However, supportive care- including ventilation strategies- can play a big role in the outcome of 
ALI, and due to advances in our understanding of supportive care, the mortality rates of ALI 
have dropped from 67% in 1990 (71) to roughly 25-30% in 2006 (72, 73). 
Appropriate use of mechanical ventilation in ALI and ARDS patients has been disputed.  
Because there is extensive damage to the lung tissue in these patients, they are predisposed to 
barotraumas, particularly at high tidal volumes and pressures while on mechanical ventilation.  A 
recent study has suggested that ventilation with lower tidal volumes (6 mL per kg of predicted 
body weight versus a normal volume of 12 mL per kg) can result in a 22% reduction in mortality 
(74).  In addition to low tidal mechanical ventilation, some studies have confirmed a benefit for 
restricting fluids in patients with ALI, presumably by decreasing the pulmonary edema (75).  
While improvements in supportive care may serve to lower the mortality rates, it is important to 
note that patients who recover from ARDS may have long-term sequelae, including 
abnormalities in pulmonary function and exercise endurance as well as an impaired quality of 
life (76, 77).   
Treatments targeting the immunopathology of ALI have not shown much benefit.  In 
particular, studies of anti-inflammatory agents and antioxidant therapies have shown no benefit 
(2, 78, 79).  It may be, though, that these treatments may be beneficial in some subset of ALI 
patients, but that this benefit is masked when looking at a heterogenous study population.  For 
 7 
instance, anti-inflammatory agents might be useful in curtailing excessive neutrophil activity, but 
patients with bacterial pneumonias may do worse because neutrophils are a key component to 
clearing the bacterial infection.  In contrast, studies have shown a benefit to the use of 
corticosteroids in preventing the fibroproliferation seen following ALI (80, 81). 
Other therapies that have failed to show a benefit in ALI include surfactant therapy (82) 
and administration of inhaled nitric oxide and other vasodilators (83, 84).  Studies have also been 
aimed at accelerating the removal of the pulmonary edema using beta-agonists, which may also 
increase surfactant secretion and even have an anti-inflammatory effect (85).  Also, experiments 
have shown that treatment with keratinocyte growth factor can protect against lung injury by 
increasing the proliferation of type II alveolar epithelial cells and increasing the clearance rate of 
alveolar fluid (86).  Interestingly, an antioxidant effect was also observed (87).  These 
experiments suggest that future clinical studies with beta-agonists and keratinocyte growth factor 
may be useful. 
 
1.1.5 Acute Lung Injury: Summary 
 
Acute lung injury is a serious clinical condition, characterized by an acute onset of hypoxia, with 
bilateral infiltrates and no evidence of increased left atrial pressures.  The most severe form of 
acute lung injury is referred to as acute respiratory distress syndrome and is characterized by 
more severe hypoxia.  Over 60 causes of acute lung injury have been identified, but most cases 
tend to result from just a handful of causes, including sepsis, bacterial or viral pneumonias, 
aspiration of gastric contents, severe trauma or burns, high volume blood transfusions, or drugs. 
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Regardless of the cause, the underlying mechanism of lung injury is fairly conserved.  
Damage to the alveolar epithelium and leakiness of the vascular endothelium contribute to 
flooding of the airspace.  Additionally, loss of type II pneumocytes results in a loss of surfactant 
production and impairs fluid reabsorbtion.   Dysregulation of the proinflammatory cytokine 
response both by resident cells such as fibroblasts and epithelial cells, as well as by inflammatory 
cells is observed, as is an excessive neutrophil response.  This neutrophil infiltration is both in 
response to and contributes to the production of proinflammatory cytokines.  Further, neutrophils 
produce reactive oxygen species that damage the cells of the lung and proteases that are able to 
destroy connective tissues. 
Unfortunately, treatment options are limited.  In addition to treating the underlying cause 
of the lung injury, treatment mainly consists of supportive mechanical ventilation.  Using lower 
tidal volumes during mechanical ventilation has been shown to result in lower mortality rates.  
While our insights into ventilation strategies have advanced, the mortality rate for acute lung 
injury is still near 30%.  There exists a need to develop therapies targeted at the lung injury 
process. 
 
 
1.2 Influenza 
 
1.2.1 Influenza Epidemiology 
 
Influenza viruses circulate in the human population and generally cause an acute respiratory 
infection.  Seasonal influenza outbreaks occur every winter and generally have attack rates of 10-
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20% of the population.  Global pandemics occur far less often, at variable intervals, and may 
have attack rates exceeding 50%.  An important consideration in determining the incidence of 
influenza infection is that many cases go unreported, as most seasonal strains are self-resolving 
in otherwise healthy individuals.  Seasonal outbreaks generally peak over a 2-3 week period and 
can last as long as 2-3 months.  Often, the first indication of a seasonal influenza outbreak is an 
increase in the number of children presenting with febrile respiratory illness, and is then 
followed by increases in presentation of flu-like symptoms in adults (88-90). 
The degree of morbidity and mortality of each influenza outbreak depends largely on the 
pathogenicity of the circulating strain of the virus, with age and immune status of the infected 
host playing a big role in outcome.  In general, influenza B outbreaks tend to be less widespread, 
and the disease less severe, than influenza A outbreaks (91).  The elderly and those with other 
underlying co-morbidities tend to experience higher levels of morbidity and higher mortality 
rates (92).  Over a period of 20 years (1972-1992) there were 426,000 deaths from influenza in 
the United States (93).  More recent numbers suggest that there was an average of 226,000 
hospitalizations per year due to influenza in the United States between 1979-2001 (88).  Costs 
have been estimated to be as high as $12 billion per year for the management and treatment of 
influenza cases each year in the United States.  It is estimated that a pandemic with attack rates 
between 35-50% would cost the United States $71-167 billion (94). 
Clinical manifestations of influenza infection can vary, particularly in severity.  
Generally patients experience an acute onset of systemic symptoms, including headaches, fevers, 
chills, myalgia, and malaise.  This is accompanied by respiratory symptoms, including a sore 
throat and cough.  As previously mentioned, in milder cases of influenza, patients may not seek 
care, as the symptoms are similar to a common cold.  In other cases, patients may experience 
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severe symptoms and have fevers as high as 41°C (105.8°F).  In uncomplicated cases, symptoms 
resolve over 2-3 days, though a sore throat or persistent cough may last for a week or more (88). 
In elderly patients, influenza infection carries a risk of pneumonia (92).  This can be 
broken down into two main categories: primary influenza viral pneumonia and secondary 
bacterial pneumonia.  Primary influenza viral pneumonia is less common, but more severe.  In 
the case of secondary bacterial pneumonia, the most common pathogens are Streptococcus 
pneumoniae, Staphylococcus aureus, and Haemophilus influenzae.  The patient generally shows 
improvement over 2-3 days before suddenly becoming febrile again and developing symptoms of 
pneumonia, including a productive cough (88, 92, 95-97). 
Other complications from an influenza infection can include exacerbation of chronic 
obstructive pulmonary disease (COPD) or asthma, sinusitis, or otitis media (middle ear 
infection).  Rarely are there extrapulmonary complications, including myositis, rhabdomyolysis, 
myocarditis, pericarditis, or encephalitis (88, 97). 
 
1.2.2 Influenza Virus Biology 
 
The influenza viruses are divided into 3 genera: influenza A, influenza B, and influenza C.  
These viruses are members of the Orthomyxoviridae family.  The virions are spheres that are 
approximately 100nm in diameter and are surrounded by a lipid envelope.  Two surface proteins- 
hemagglutinin (HA) and neuraminidase (NA) protrude from this envelope to interact with the 
surface of host cells.  The influenza genome is unique in that it consists of 8 single-stranded 
negative-sense RNA segments which encode for 10 viral proteins. 
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The three largest genome segments encode the proteins PB2 (759 amino acids), PB1 (757 
amino acids), and PA (716 amino acids), all of which are subunits for the viral RNA polymerase.  
The next largest segment encodes the HA protein (566 amino acids), a surface protein that exists 
as trimers and binds to host cells (described in greater detail later).    Nucleoprotein (NP, 498 
amino acids) is encoded by the 5th RNA segment and encapsidates each RNA segment.  The 6th 
RNA segment encodes the NA protein (454 amino acids) which is the other surface protein, 
expressed as a tetramer and critical to the release of viral progeny.  Genome segment 7 encodes 2 
proteins due to alternative splicing: matrix (M1) protein (252 amino acids) which is an important 
structural component of the virion, and M2 (97 amino acids), which forms a tetramer and serves 
as an ion channel.  The 8th and final segment of the genome also encodes for two proteins: NS1 
(230 amino acids), which plays a role in inhibiting the interferon response to the virus, and NS2 
(121 amino acids), which is involved in export of viral RNA to the host cell nucleus (98-100). 
Viral replication takes place in respiratory epithelial cells.  The HA trimers on the virion 
surface bind to sialic acid residues on the host cell and the virus enters via endocytosis.  Once 
inside the endosome, the M2 protein serves as a channel for protons, resulting in the acidification 
and uncoating of the virion.  The viral membrane fuses to the endosomal membrane and allows 
for the export of viral RNA- bound to NP and NS2 proteins- into the cytoplasm.  These 
ribonucleocapsids enter the nucleus through nuclear pores and are transcribed in the nucleus.  
One unique feature of influenza RNA transcription involves “cap stealing”, whereby the PB2 
protein binds to the caps of host mRNA and uses them to prime transcription of viral mRNAs.  
These viral mRNAs are then translated to make viral proteins, and also serve as template for the 
generation of negative-sense viral RNA.  Virion assembly occurs in the cytoplasm, and newly 
assembled virons bud from the host cell.  HA proteins on the new progeny virions also bind to 
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the sialic acid residues of the host cell; therefore, cleavage by NA is necessary for release of the 
virion (98). 
 
1.2.3 Genetic Reassortment 
 
Influenza viruses are further subtyped based on their surface (HA and NA) antigens.  By 
convention, each HA and NA subtype is numbered, and viral strains are referred to as HxNx (for 
example, H1N1 or H3N2).  While there are 16 different HA subtypes, only H1, H2, H3, and 
recently H5 have been shown to cause outbreaks in humans.  Similarly, though there are 9 
distinct N subtypes, only N1 and N2 have been identified in human outbreaks (88). 
New strains of influenza result from two distinct processes of genetic variation: antigenic 
drift and antigenic shift.  Antigenic drift is a gradual process that, in essence, is the accumulation 
of point mutations within a virus over multiple generations.  This is particularly apparent in the 
HA and NA proteins; the other viral proteins are comparatively highly conserved.  Antigenic 
drift is helped by the fact that influenza’s RNA polymerase is rather error prone.  The amino acid 
substitutions in HA range from 1.9-3.0 x 10-3 per year, whereas for the more highly conserved 
M1 protein, amino acid substitutions average 3 x 10-5 per year.  Overall, the influenza genome 
averages 0.5 x 10-3 per year (101, 102). 
Antigenic shift is a process unique to influenza’s segmented genome.  Antigenic shift 
occurs when two viral subtypes co-infect the same organism.  When progeny virions of two 
influenza subtypes are replicating and being packaged within the same cell, it is possible that 
segments of one subtype’s genome get packaged with another subtype, and was first 
demonstrated over 50 years ago (103).  For example, in a cell infected with both H1N1 subtypes 
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and H3N2 subtypes, it would be possible for the HA and NA genomic segments to get 
“switched”, resulting in not only H1N1 and H3N2 progeny, but also H1N2 and H3N1 progeny.  
This resulting “shift” explains how new subtypes of virus are able to rapidly emerge in the 
population. 
 
1.2.4 Animal models of influenza infection 
 
For the sake of brevity, only the three most commonly used models of influenza will be 
discussed: mice, ferrets, and nonhuman primates.  Of these, the mouse is perhaps the most 
commonly used model of influenza infection.  The advantages of using mice are that they are 
inexpensive, easy to house, and many reagents are available to evaluate the immune response.  
Mice are not natural hosts for influenza, however, which necessitates adapting the virus by 
several passages.  Additionally, mice are generally inbred, a fact that must be considered when 
translating data to heterogenous human populations (104). 
One of the most commonly used mouse adapted strain is influenza A/Puerto Rico/8/34 
(H1N1).  Innoculation with mouse adapted strains of influenza results in an illness generally 
similar to human disease, with similar histopathology and reduced blood oxygen saturation 
levels.  However, mice generally do not exhibit fever, sneezing, coughing, or dyspnea.  Useful 
outcome measures to determine disease severity include weight loss, viral titers, average time to 
death, lung pathology scores, cellular recruitment to the airway, and markers of lung injury, 
including total protein and LDH in the bronchoalveolar lavage fluid (104-106). 
In contrast to the mouse, the ferret is an animal model that displays many symptoms 
similar to human disease.  Influenza virus-infected ferrets exhibit nasal discharge, fever, and 
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watery eyes, along with anorexia.  Also unlike mice, ferrets are able to spread the virus among 
themselves, even in separate- but connected- cages (104, 107).  Ferrets are used less frequently 
than mice for many logistical reasons.  First, they are more aggressive and difficult to work with, 
they are more expensive to house, it can be difficult to obtain specific pathogen-free animals, and 
reagents for evaluating the ferret immune response are not as extensive as those for mice (108). 
Nonhuman primates are also used as a model for human influenza infection, with rhesus 
macaques and cynomolgus macaques being the most commonly used species (36, 109).  The 
chief benefit to this model is that they are more closely related to humans than other small 
mammals.  Drawbacks are similar to those of the ferret model, specifically costs and difficulties 
associated with obtaining and housing the animals and availability of reagents (108). 
Other less studied models of influenza infection include rats, pigs, cats, and dogs.  
Additionally, development of vaccines for avian influenza has included studies in several avian 
species (108). 
 
1.2.5 Influenza: Immune Response- Innate Mechanisms 
 
The immune response to the influenza virus, like those in response to most pathogens, is 
complex and multifaceted.  Both innate and adaptive mechanisms are important in viral 
clearance.  While neither “arm” of the immune system works independently, for the sake of 
clarity, the description of the immune response will be broken down into innate mechanisms, T 
cell roles, and B cell and antibody roles. 
The innate response to influenza begins with the cells that are the primary targets of 
infection: the respiratory epithelial cells.  Influenza virus stimulates epithelial cells through Toll-
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like receptor (TLR)-3, whose primary ligand is dsRNA.  TLR-3 is expressed intracellularly in 
human pulmonary epithelial cells, and is upregulated upon infection with influenza (110).  
TLR3, unlike other TLR’s, signals through TRIF as opposed to MyD88.  While TLR3 plays a 
role in activating epithelial cells, it is interesting to note that mice lacking TLR3 have less 
inflammation and higher viral burdens, but perhaps paradoxically have a survival advantage 
(111). 
Upon infection with influenza virus, these epithelial cells activate a number of 
transcription factors that induce cytokine and chemokine production, including nuclear factor 
kappa B (NF-κB), interferon regulatory factors (IRFs), signal transducers and activators of 
transcription (STATs), and activating protein (AP)-1 (112, 113).  This leads to the production 
and release of a variety of proinflammatory mediators, including IFN-α, IFN-β, IL-6, CXCL8 
(IL-8), CXCL9 (MIG), CXCL10 (IP-10), and CCL5 (RANTES) (114, 115).   
Perhaps most importantly, these epithelial cells upregulate type I interferons (IFN-α and 
IFN-β).  These type I interferons subsequently induce the expression of Mx proteins, which 
inhibit the transcription of influenza genes by complexing with the viral NP protein.  Mx1-null 
mice have in fact been shown to be more susceptible to influenza infection (116, 117).  It is also 
important to note that the influenza NS protein is capable of antagonizing type I interferons, 
thereby promoting viral replication (118, 119).  
Alveolar macrophages also play an important role in the innate response to influenza.  
Like epithelial cells, alveolar macrophages can be infected by influenza virus.  Also like 
epithelial cells, these alveolar macrophages are an important source of proinflammatory 
mediators, particularly TNF-α, IL-1β, IL-6, type I interferons, CCL4 (MIP-1), CCL5 
(RANTES), and CXCL10 (IP-10) (113, 120-122).  In contrast to epithelial cells, macrophage 
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death is almost exclusively apoptotic (123).  The apoptotic and necrotic death of epithelial cells 
and alveolar macrophages also serves as another trigger for the release of proinflammatory 
cytokines and chemokines.  In fact, caspase-1 activation- which is associated with apoptosis- 
appears to be important in achieving efficient production of both IL-1β and IL-18 (124). 
In vivo, the release of the cytokines and chemokines by epithelial cells and macrophages 
leads to the recruitment of monocytes and neutrophils- as well as T cells at later time points- into 
the lung (122).  Given the role of neutrophils in ALI, their role in influenza infection is of 
particular interest.  Their ability to bind and take up influenza virus in the absence of antibody 
opsonization (125) is important to their role in early control of viral infection.   
It has been shown that influenza is capable of activating the neutrophil, resulting in the 
production of multiple antimicrobial products.  One such example is α-defensins- a group of 
small cationic antimicrobial peptides that have shown to be active against a wide spectrum of 
gram-negative and gram-positive bacteria, fungi, parasites, and viruses.  While α-defensins may 
be capable of binding to and disrupting the lipid envelop of viruses (including influenza), it 
appears that these peptides may also exert their anti-viral activity by affecting the target cell and 
inhibiting viral replication (126).  Additionally, α-defensins increase neutrophil uptake of 
influenza virus and may play a role in the respiratory burst response (125).  Further, defensins 
may modulate the immune response, as they are chemotactic for human T cells, monocytes and 
immature dendritic cells (127). 
In addition to the production of defensins, influenza also stimulates an oxidative burst in 
neutrophils.  Both reactive oxygen intermediates (ROI) and reactive nitrogen intermediates have 
been implicated in lung damage following influenza infection.  The primary product of the 
neutrophil’s respiratory burst in response to influenza is hydrogen peroxide (H2O2) (128).  
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Production of superoxide anion (O2-) is less defined, with some reports suggesting neutrophils do 
make superoxide anion when stimulated with influenza (129, 130) and others reporting they do 
not (128).  The latter is consistent with other reports that demonstrate defects in neutrophil 
chemotactic, oxidative, and bacterial killing functions following influenza infection (131, 132).  
Additionally, stimulation with influenza accelerates neutrophil apoptosis (133).  The neutrophil 
dysfunction induced by influenza may partially explain why influenza-infected hosts are more 
susceptible to secondary bacterial infections (131, 132, 134, 135). 
 
1.2.6 Influenza: Immune Response- T cells 
 
The T cell response to influenza involves both CD4+ T helper (Th) cells and CD8+ cytotoxic T 
lymphcytes (Tc or CTL), with both types of effector cells playing key roles in resolution of 
infection.  In general, CD4+ and CD8+ T cells do not arrive at the site of infection in the lung 
until approximately 4 days post-infection, and these populations peak around 10 days post-
infection, which coincides with clearance of sublethal infections (136, 137).  In terms of 
magnitude, the CD8+ T cell response is larger than the CD4+ T cell response (138).  Further, 
while roles for both CD8+ T cells and CD4+ T cells have been established in viral clearance, 
mice lacking one subset or the other still clear infection, albeit with some delay.  In contrast, 
mice lacking both CD4+ and CD8+ T cells do not survive influenza infection (139). 
CD4+ T cells recognize antigen in the context of major histocompatibility complex 
(MHC) class II molecules on the surface of antigen presenting cells.  Because there is no viral 
replication in lymphoid tissue, antigen presentation to CD4+ T cells is dependent on dendritic 
cell trafficking from the lung.  This begins within 36 hours of viral infection, and antigen 
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presenting cells (APCs) are detected throughout the resolution of viral illness (10-14 dpi) (140).  
Studies in CD4+ T cell receptor (TCR) transgenic animals have even suggested that APC’s are 
present and capable of stimulating T cells as late as 3 weeks post-infection (141).   
CD4+ T cells are further subdivided into multiple subsets based on their cytokine 
production, including Th1 cells (producing IFN-γ, IL-2, and TNF-α), Th2 cells (IL-4, IL-5, IL-
13), Th17 cells (IL-17, IL-22), and Treg (IL-10, TGF-β) among others.  Th1 cells tend to 
promote activation of CD8+ T cells and macrophages as well as influence B cell differentiation 
towards production of IgG2a, whereas Th2 cells tend to influence B cell differentiation towards 
IgG1 an IgE, as well as activate eosinophils.  Th17 cells tend to result in neutrophil recruitment, 
and while Tregs generally dampen the immune response (reviewed in (142-145). 
Using HA-specific TCR transgenic CD4+ T cells, it has been demonstrated that the Th1 
response is dominant in response to influenza infection (146, 147).  Further, while adoptive 
transfer of influenza-specific Th1 cells has been shown to be protective, adoptive transfer of 
influenza-specific Th2 cells is not protective, and in fact resulted in delayed viral clearance and 
excessive congestion of the lung (148).  The role of Th17 cells in influenza infection remains 
undescribed.   
Because the predominant cytokine of a Th1 response is IFN-γ, further studies examined 
IFN-γ null mice, and found that loss of IFN-γ results in increases in Th2 cytokine production.  
However, cytotoxic T cell responses were similar to wild-type mice.  Further, CD4+ T cells from 
these IFN-γ knockout mice were still protective, and in fact demonstrated a cytolytic ability 
(149). Additional studies have also shown that IFN-γ is dispensable for the cytolytic ability of 
these cells.  More recent studies seeking to understand the mechanism by which CD4+ T cells 
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can exert cytotoxicity have shown that CD4+ effector T cells that are primed in vitro are capable 
of acquiring perforin-mediated cytotoxicity, and that this ability is maintained in vivo (150). 
As alluded to previously, in addition to this direct cytotoxic effect, CD4+ T cells also 
play other roles in the clearance of influenza.  CD4-depleted mice are still capable of clearing 
influenza, suggesting that CD4+ T cells are not required for survival (151).  Further, mice 
lacking both CD8+ T cells and B cells do not survive influenza challenge, suggesting that CD4+ 
T cells alone are also not sufficient for viral clearance (152).  However, there is ample evidence 
for the role of CD4+ T cells in helping B cells and CD8 T cells.  Mice lacking CD8+ T cells can 
survive influenza challenge, but that ability is compromised by depletion of CD4+ T cells, 
providing evidence that B cells alone, without CD4+ T cell help, are not sufficient (139, 152, 
153).  Similarly, mice lacking B cells are able to clear influenza, but when depleted of CD4+ T 
cells cannot, suggesting that the CD8+ T cell response also requires CD4+ T cell help (151). 
Multiple studies have confirmed the role of CD4+ T cells in helping to promote the B cell 
response to influenza.  Adoptive transfer of CD4+ T cells results in antibody titers that are 10- to 
50-fold higher than control mice (150).  More specifically, titers of IgG2a are increased, 
reflecting the skewing towards a Th1 response.  In contrast, mice receiving CD4+ T cells that are 
IFN-γ – deficient produce higher levels of IgG1, reflecting a Th2 predominance.  This CD4+ T 
cell-dependent antibody response is important in viral clearance, as mice lacking B cells were 
not protected by transfer of CD4+ T cells (150).  Other studies have shown that influenza-
specific antibody titers are decreased in thymectomized mice or mice lacking T cells (154, 155). 
CD8+ T cells have been demonstrated to be protective, principally through cytolytic 
mechanisms.  CTLs recognize antigen in the context of MHC class I molecules, which can be 
expressed by nearly all nucleated cells, including the respiratory epithelium.  Virus-specific 
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CD8+ T cells are capable of killing infected cells both through Fas/FasL and perforin-dependent 
mechanisms (156, 157).  The CTL response is generally directed towards conserved epitopes of 
internal proteins, including NP and matrix protein, which allows for a degree of heterosubtypic 
immunity (158).  Similar to CD4+ T cells, CD8+ T cells are subclassified into analogous Tc1 
and Tc2 subtypes based on their cytokine profiles.  Interestingly, Tc1 and Tc2 cells are both 
protective, but Tc1 cells are more effective at reducing viral load, and are predominantly 
localized at the respiratory epithelium.  In contrast, Tc2 effector cells are found predominantly in 
the interstitial space of the lung (137, 159). 
A recent report has established a third subtype of CD8+ T cells: Tc17 cells.  These cells 
are analogous to Th17 cells in terms of cytokine profile.  Tc17 cells generated in vitro are 
protective against influenza challenge when adoptively transferred.  Interestingly, these cells lack 
perforin or granzyme B and do not display cytolytic activity.  Protection is assumed to be 
through the recruitment of neutrophils by production of IL-17 (160). 
It is also important to note that CD8+ T cells have been implicated in the 
immunopathology of influenza infections.  This immunopathology is due, at least in part, to the 
antigen-specific production of TNF-α by these CD8+ T cells.  Antibody neutralization of TNF-α 
or loss of TNF receptor-1 (TNFR-1, or p55) is able to eliminate this immunopathology.  In 
response to membrane-bound TNF-α on the CD8+ T cell, alveolar epithelial cells produce MCP-
1 and MIP-2, resulting in increases in the number of inflammatory cells recruited to the lung. 
Interestingly, it is also suggested that TNF-α is dispensable for CD8+ T cell antiviral activity, 
raising the possibility of targeting TNF-α to protect against immunopathology without 
interfering with viral clearance (161, 162). 
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One additional class of T cells is the γδ T cells.  These differ from CD8+ and CD4+ T 
cells in multiple ways, the first being that their TCR is composed of γ and δ chains, as opposed to 
α and β.  Their receptor diversity is much more limited, and thus these cells are often thought of 
as innate-like lymphocytes.  Additionally, these cells are capable of recognizing target antigens 
directly, as opposed to bound to MHC molecules.  Not much literature exists in describing the 
role of these cells in influenza infection (163), though it has been reported that these cells may 
respond to endogenous antigens such as heat shock proteins, which are upregulated during 
influenza infection (164).   
 
1.2.7 Influenza: Immune Response- B cells and Antibodies 
 
B cells contribute to the immune response to influenza in several distinct ways.  First, it has been 
shown that B cells can produce a number of cytokines, including IL-2, IL-4, IL-6, IL-10, TNF-α, 
and IFN-γ (165).  Further, B cells are capable of presenting antigen via MHC class II (166) and 
providing costimulation to T cells (167).  However, their major role in most immune responses is 
production of antibody.  Antibodies are capable of neutralizing and opsonizing antigen, and are 
therefore a key player in antigen clearance (139, 168). 
Studies of B cell deficient (μMT) mice have produced mixed results.   Some studies have 
reported that these mice have difficulty clearing virus and increased mortality (151, 169) while 
others show minimal differences from wild-type controls (170-172).  However, adoptive transfer 
of influenza-specific IgG antibodies to SCID mice is protective in the influenza model, 
indicating a beneficial role for a B cell response.  In contrast, influenza-specific IgM antibodies 
do not provide protection to SCID mice, indicating that only isotype-switched antibodies are 
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effective in viral clearance (173).  Antibody class switching requires T cell help, and in mice 
lacking T cells, influenza-specific antibody titers are much lower (154, 155).  However, there are 
reports demonstrating that there is some protective CD4+ T cell-independent antibody response 
(174, 175). 
Both influenza-specific IgA, found mainly in mucosal surfaces, and systemic IgG are 
capable of recognizing and neutralizing influenza virus (176, 177).  However, there are two 
weaknesses to the antibody response.  First, antibodies are generally directed to the surface 
proteins of influenza, HA and NA.  As discussed above, these antigens are highly variable, and 
due to genetic shift and genetic drift, differ between different strains of the virus.  As a result, 
antibodies to one strain may not have much cross-reactivity, and therefore offer little protection, 
against a different strain.  However, reports have suggested that preexisting antibodies are able to 
offer early control over viral replication even if there is only partial cross-reactivity (176). 
The second weakness to the antibody response to influenza is the fact that there is a delay 
between the time of infection and the time when antibody titers are able to be measured.  
Significant titers of class-switched antibodies generally do not appear until late in the infection, 
not peaking until 10 days post-infection or later, after the virus has been cleared (178, 179).  This 
implies that antibody production is not a significant factor in the clearance of a primary influenza 
challenge.  Instead, the value of the antibody response appears to be secondary protection against 
re-infection.  Indeed, virus-specific IgG can be detected in the serum for years following 
infection.  Studies in the mouse have demonstrated that these antibodies come from plasma cells 
in the bone marrow that are generated in response to viral infection and are long-lived (180). 
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1.2.8 Influenza: Immune Response- Memory 
 
Virus-specific antibody titers are detectable for years after infection (139, 168, 180), and indeed, 
adoptive transfer of IgG from animals that have been infected with influenza is protective in 
naïve animals, including SCID mice (173).  This demonstrates that the humoral memory 
response is capable of providing protection against re-infection (139).  This humoral response is 
the main mechanism by which current vaccines confer protection.  However, as previously 
discussed, this is limited by the fact that the antibody response is directed against the HA and NA 
surface proteins of the influenza, and that these proteins are highly variable between different 
strains of the virus.  Thus, current vaccines would not be protective in the case of the emergence 
of a reassortant virus (181). 
Because the CD8+ and CD4+ T cell response is directed towards internal viral proteins 
that are more highly conserved, it stands to reason that T cell memory is capable of providing 
broader protection against a wider variety of influenza strains (182).  The effector CD4+ T cell 
response rapidly transitions to a resting population with memory characteristics following viral 
clearance (136, 183).  Though the frequency of CD4+ memory cells is lower than that of CD8+ 
memory cells (138), they are still detectable both in the lung and in secondary lymphoid tissues, 
including spleen and lymph nodes.  CD4+ memory cells in the lung express high levels of CD43 
and low levels of CD62L and CCR7, whereas CD4+ cells in the spleen and lymph node are more 
typical of central memory cells, expressing high levels CD62L and CCR7.  These phenotypical 
differences suggest that there may be functional differences between different memory 
populations that is site-specific (184). 
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The CD8+ T cell response does not undergo the same magnitude of contraction that the 
CD4+ T cell response does; therefore, CD8+ memory T cells are generally detectable at higher 
frequencies (138).  Similarly, CD8+ memory cells can be found both in the lung and lymphoid 
tissue (185).  Upon secondary challenge, there is rapid proliferation of the CD8+ T cell 
population.  Interestingly, both the size of the resting CD8+ memory T cell pool and the 
magnitude of the recall response are diminished in mice lacking CD4+ T cells, illustrating a role 
for CD4+ T cells in supporting CD8+ T cell memory responses (186). 
 
1.2.9 Highly virulent strains of influenza 
 
While seasonal outbreaks of influenza occur every year, it is important to note that strains 
capable of producing global pandemics circulate at irregular intervals.  Perhaps the worst of 
these was an outbreak of an H1N1 strain that occurred in 1918 in what is commonly referred to 
as the Spanish Flu, despite the fact that there is no evidence that it originated in Spain.  It has 
been estimated that anywhere from 20-50 million people died from this pandemic (32, 187).  In 
contrast to most seasonal strains, where mortality is highest among the elderly, the 1918 
pandemic saw significant mortality among young adults (188).  Re-creation of the 1918 
pandemic strain (189) has allowed for the study of differences between this highly pathogenic 
strain and more typical, interpandemic strains. 
One major difference observed between the 1918 H1N1 strain and interpandemic strains 
is an increased rate of viral replication (190).  This may be one trigger that results in an early and 
sustained abberant innate immune response that is associated with the increased pathology.  In 
what is commonly referred to as a “cytokine storm”, there are marked elevations of several 
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proinflammatory cytokines, including TNF-α, IL-1, and IL-6 (38, 191).  In mice, it has been 
reported that there is an excessive infiltration of macrophages and neutrophils in the lung (38, 
39).  Similarly, studies in nonhuman primates revealed increases in inflammation, with higher 
levels of CCL2, CCL5, IL-8, and IL-6 (36). 
Strains of H5N1 influenza currently circulating in avian populations- though also capable 
of causing fatal disease in humans- also display highly pathogenic characteristics.  Similar to the 
1918 H1N1 strain, H5N1 influenza infection in mice results in excessive macrophage and 
neutrophil recruitment to the lung (39) as well as higher levels of proinflammatory cytokines (39, 
192, 193).  High levels of TNF-α, IFN-γ, and IL-6 were also described in serum from patients 
infected with H5N1 in Hong Kong during outbreaks in 1997 (194).  Additionally, H5N1 strains 
may also be capable of disrupting immunity beyond the innate response, as infection of dendritic 
cells has been noted in H5N1 infection (39). 
Fortunately, human to human transmission of H5N1 strains is rare, and generally requires 
intimate contact (28).  This is thought to be due to receptor binding specificities of the H5 
molecule.  This form of hemagglutinin predominantly recognizes α2-3-bound sialic acids, 
whereas α2-6-bound sialic acids are dominant in the human upper respiratory tract.  There are, 
however, α2-3-bound sialic acid residues in the lower respiratory tract, meaning that if the 
innoculum is heavy enough and deep enough, it will cause disease (195, 196).  There is fear that 
through antigenic drift and antigenic shift that H5N1 strains could adapt to recognize α2-6 
residues and subsequently evolve into a serious pandemic. 
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1.2.10 Current treatment and vaccination strategies 
 
In the case of uncomplicated influenza, treatment options are generally supportive- hydration and 
symptom-based therapy with acetaminophen.  In the case of severe cough, codeine-containing 
cough suppressants are often used (88).  Specific antiviral therapy is available in the form of 
neuraminidase inhibitors zanamivir and oseltamivir.  Use of these agents can decrease the 
duration of symptoms by as much as two days if begun within 48 hours of onset of symptoms 
(197, 198).   
In the past, amantadine and rimantadine have been used to treat influenza.  The presumed 
mechanism of action was interference with the viral M2 protein, which blocked viral uncoating 
and replication.  However, resistance to these drugs is very high (>90% of H3N2 viral isolates in 
2005-2006 were resistant to amantadine) and therefore they are no longer recommended for 
treatment.  In addition to antiviral drugs, antibiotics should be used for the management of 
secondary bacterial infections.  The use of a specific antibiotic should be determined by the 
bacterial species causing disease (88). 
Influenza vaccination is perhaps the best weapon we have against the virus.  Vaccination 
strategies against influenza are unique among all other vaccination strategies in that a new 
vaccine must be given each year.  This is because antigenic drift and antigenic shift result in 
strains that may not be covered by the antibody response to previous vaccines.  This also requires 
epidemiologists to accurately identify the predominant circulating strains of influenza prior to the 
“flu season” for the vaccine to be effective (88, 199).  Ongoing research seeks to develop better 
vaccines that prime both a humoral and cellular immune response.  This includes development of 
both DNA-based vaccines (182) and non-infectious influenza virus-like particles (200-202). 
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Currently, both inactivated and live viral vaccines are available.  In both cases, the 
vaccine is a mixture of influenza A and B strains thought to predominate, and they are highly 
effective if the vaccine strains closely match the circulating strains.  Vaccination is 
recommended for children, elderly, and immunocompromised patients, as well as patients who 
have any chronic pulmonary disorders that may predispose them to infection.  Additionally, 
vaccination is recommended for health care workers and people who live with or care for high-
risk patients (199). 
 
1.2.11  Influenza: Summary 
  
Influenza is an enveloped, negative-sense segmented RNA virus capable of causing infection in 
the respiratory tract by infecting respiratory epithelial cells.  Severity of influenza infection can 
range from subclinical to fatal.  Outbreaks of seasonal strains of influenza occur annually in the 
winter months, while more severe pandemic strains occur at irregular intervals over periods of 
decades.  Seasonal outbreaks tend to affect the elderly and immunocompromised 
disproportionately, whereas pandemic strains have historically had higher mortality rates, 
including mortality among young adults.  The immune response is multifaceted and complex, 
involving contributions from alveolar epithelial cells and macrophages, neutrophils, CD4+ T 
cells, CD8+ T cells, and B cells (and antibodies).  Dysregulation of this immune response, 
particularly the neutrophil and CD8+ T cell response, may be responsible for much of the 
immunopathology observed in severe cases of influenza. 
 Currently, vaccination is the most useful method of combating the spread of 
influenza.  Unfortunately, the virus is continually changing its antigenic epitopes- through 
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genetic shift and genetic drift- necessitating updated vaccines each year.  Treatment of influenza 
is generally supportive and consists of hydration and symptom-dependent use of acetaminophen.  
The only virus-specific treatment available is the use of neuraminidase inhibitors, as influenza 
has become resistant to amantadine. 
 
 
1.3 Interleukin-17 and Interleukin-17 Receptor A Signaling 
 
1.3.1 Discovery and Cellular Sources of Interleukin-17 
 
IL-17, also known as IL-17A, was first cloned in 1993 and identified as cytotoxic T-lymphocyte-
associated antigen (CTLA)-8.  It was found to have high similarity with open reading frame 13 
of Herpesvirus saimiri, a virus capable of inducing T cell lymphomas in several species of 
primates.  In humans, the gene for IL-17 was mapped to chromosome 2q31 (203, 204).  
However, subsequent studies have identified the gene on chromosome 6 (205, 206).  Mouse and 
human IL-17 exhibit 63% amino acid homology (207).  Since the discovery of IL-17, several 
other homologous proteins have been identified, resulting in an IL-17 cytokine family in which 
the members are designated IL-17A through IL-17F (206, 208-210).  IL-17A and IL-17F share 
the greatest homology and are perhaps the best characterized cytokines in the family (206).  
These two molecules may also heterodimerize (211).  In contrast, IL-17E- also referred to as IL-
25- is the most divergent member (212). 
IL-17 was first shown to be produced by activated CD4+ T cells (213).  Since that 
discovery, it has been determined that CD4+ T cells producing IL-17 constitute a distinct 
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lineage, referred to as Th17 cells (in contrast to Th1 or Th2 cells) (reviewed in (214-216).  Th17 
cells produce both IL-17A and IL-17F (along with other cytokines), though subsets producing 
only IL-17A or IL-17F have also been described (217).  These cells are described in more detail 
below. 
Other cell types have also been described to produce IL-17.  These include invariant 
NKT cells (218) and CD8+ T cells (219).  In fact, a recent report has identified a subset of CD8+ 
cells that produces IL-17 and termed them Tc17 cells (160), following the convention of CD4+ T 
cell lineages.  γδ T cells have also been described as an important source of IL-17 in multiple 
models (220-223).  IL-17 mRNA has also been measured in neutrophils in response to challenge 
with lipopolysaccharide (LPS) (224), though production and secretion of IL-17 protein by these 
cells has not been described. 
Other isoforms of IL-17 have different expression patterns.  In the case of IL-17B, 
mRNA has been detected in a wide variety of tissue, including the gastrointestinal tract, prostate, 
ovary, testis, and spinal cord (208).  In contrast, IL-17C expression is much rarer, having only 
been identified in prostate and fetal kidney (208).  IL-17D is expressed in muscle and adipose 
tissue as well as brain, lung and pancreas (210, 225).  IL-17E (IL-25), like IL-17A and F is 
expressed most abundantly by T cells, especially Th2-polarized CD4+ T cells (226). 
 
1.3.2 Regulation of IL-17 Production 
 
Of the various cell types that are capable of producing IL-17, CD4+ T cells are the best 
characterized producers.  Production of IL-17 by these cells is dependent upon polarization to a 
Th17 phenotype upon antigenic stimulation.  For example, polarization to the Th1 subset occurs 
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in the presence of IL-12 and results in a T cell population that produces IFN-γ and TNF-α.  
Polarization to the Th2 subset generally requires the presence of IL-4, and results in a cell 
population that produces IL-4, IL-5, and IL-13 (reviewed in .  In the presence of TGF-β alone, T 
cells polarize to regulatory T cells, producing TGF-β and IL-10 (228, 229).  In mice, the 
presence of TGF-β and proinflammatory cytokines IL-1β and IL-6, T cells polarize to Th17 cells 
and produce IL-17A and IL-17F, along with IL-21 and IL-22 (229-231).  Other studies have 
identified IL-21 as being capable of driving Th17 differentiation along an alternative pathway 
(232, 233).   
Initially, it was believed that Th17 polarization in mice also required IL-23.  However, it 
was shown that receptors for IL-23 were not present on naïve T cells (234), and subsequently 
demonstrated that IL-23 is not responsible for polarization of naïve T cells to a Th17 phenotype 
(230, 231).  Despite this, it is clear that IL-23 is important for Th17 cells, as loss of IL-23 results 
in decreased production of IL-17.  It has been shown that IL-6 and TGF-β synergize to induce 
expression of IL-23 receptor, and that subsequently, IL-23 is responsible for the expansion and 
maintenance of Th17 cells, as well as the expression of chemokine receptors on these cells (235-
237).  Further, loss of IL-23 results in a decrease of IL-7 receptor alpha (IL-7Rα), which is 
necessary for survival of memory Th17 cells, suggesting that IL-23 also supports Th17 memory 
(237). 
In humans, Th17 development can be driven by IL-1β and IL-23 (238, 239) and 
enhanced by IL-6 (240).  The role of TGF-β in human Th17 development is unclear, as some 
reports suggest TGF-β may actually suppress the generation of human Th17 cells (238-240).  
However, other studies have shown that TGF-β is necessary (241, 242).  Further, one study has 
shown that TGF-β plus IL-21 can drive human Th17 polarization (243), while another study 
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shows no IL-17 production under those conditions (242).  Reasons behind these discrepancies 
must be further explored, but may be due to differences in culture media (serum vs. serum free) 
and time of the culture (244). 
Induction of Th17 cells requires signaling through signal transducer and activator of 
transcription (STAT) 3 (245, 246), and activation of transcription factors RORγt and 
RORα (242, 247).  STAT3 is activated both by IL-6 and IL-23.  Additionally, aromatic 
hydrocarbon receptor (AhR) has been shown to be capable of stimulating Th17 differentiation 
(231).  This cytosolic receptor, once bound to an aromatic hydrocarbon ligand, translocates to the 
nucleus and serves as a transcription factor that works synergistically with RORγt and RORα.  
Even more recently, it has been shown that prostaglandin E2, acting through prostaglandin EP2 
and EP4, regulates Th17 cell differentiation (248).   
Another family of transcription factors important in T cell differentiation is the family of 
interferon regulatory factors (IRFs).  IRF1 and IRF2 have both been established to play roles in 
Th1 differentiation (249, 250).  IRF4, on the other hand, has been shown not only to promote 
development of Th17 cells but to antagonize IRF1.  IRF4-deficient mice exhibit decreased levels 
of IL-17 and IL-21.  Under conditions favoring Th17 differentiation (TGF-β and IL-6), these 
mice instead polarize towards a regulatory T cell phenotype (251).  
Production of IL-17 by γδ T cells similarly requires polarization.  Subsets of IL-17-
producing γδ cells have been identified that are distinct from those producing IFN-γ.  Further, 
these IL-17 producers are CD25+ CD122-, whereas IFN-γ producing γδ are CD25- CD122+.  In 
contrast to the αβ T cells described above, which leave the thymus as naïve cells and polarize in 
the periphery, the γδ T cells are capable of undergoing polarization in the thymus (222).  It is 
hypothesized that this allows them to be able to rapidly respond to antigen in the periphery. 
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The precise factors determining γδ polarization are not as well described as those for 
Th17 cells.  One report describes the role of thymic selection in polarization of these cells, 
demonstrating that γδ cells that are “antigen-naïve” during development produce IL-17, while 
those that encounter antigen during thymic selection instead produce IFN-γ (252).  Other studies 
have demonstrated that, similar to Th17 cells, IL-17 production by γδ cells is supported by IL-
23, and that this IL-23 signal is mediated through Tyk2 signaling (223). 
 
1.3.3 The IL-17 Receptor Family and IL-17 Signaling 
 
The first known IL-17 receptor, now known as IL-17 receptor A (IL-17RA), is ubiquitously 
expressed.  Both IL-17A and IL-17F are capable of binding IL-17RA, but at low affinities 
(affinity for IL-17F is less than that for IL-17A) (253).  However, a second IL-17 receptor, IL-
17RC, has been identified that has a much higher affinity for both IL-17A and IL-17F.  Further, 
IL-17RC, when co-transfected with IL-17RA, results in optimal signaling by both IL-17A and 
IL-17F.  Additionally, these two proteins co-immunoprecipitate, providing evidence of 
association (254).  The precise stoichiometry of this association is not determined. 
IL-17RA appears to be essential for both IL-17A and IL-17F signaling, as loss of this 
protein blocks the ability of cells to respond to these cytokines (255).   The cytoplasmic portion 
of this receptor contains a sequence similar to the TIR domains common to TLR’s and IL-1 
receptors (256). This region of the protein has been termed a “SEFIR” domain, and deletions of 
this region impair IL-17 signaling (257).  It has further been reported that the signaling protein 
Act1, which also encodes a SEFIR domain, interacts with IL-17RA and results in activation of 
NF-κB and TAK1 (258).  However, IL-17RA also has been shown to activate other signaling 
 33 
pathways, including activation of ERK (258), suggesting that other signaling motifs remain to be 
described. 
In response to IL-17RA signaling, cells produce several proinflammatory chemokines, 
cytokines, and growth factors.  Among the chemokines that are upregulated are CXCL1 (KC), 
CXCL2 (MIP-2), CXCL5 (LIX) and CXCL8 (IL-8), all of which are chemoattractive for 
neutrophils (205, 259, 260).  Additionally, G-CSF and GM-CSF are upregulated, promoting 
granulopoeisis, including neutrophil production (205, 261).  Other chemokines that are 
responsive to IL-17 signaling include CXCL9 (MIG), CXCL10 (IP-10), CCL2 (MCP-1), and 
CCL20 (MIP3α) (262-264).  Other proinflammatory cytokines produced in response to IL-17 
signaling include TNF-α and IL-6 (204, 265).  Additionally, IL-17 upregulates several acute 
phase response proteins and anti-microbial proteins, either alone or synergistically with IL-22.  
These proteins include SAA, C-reactive protein, lipocalin 2, β-defensins, S100 proteins, and 
mucins (266-271). 
 
1.3.4 Roles of IL-17 in the Lung 
 
Given the role of IL-17 in the regulation of growth factors that promote granulopoeises and 
chemokines that recruit neutrophils, it plays an important role in the neutrophil response in the 
lung.  Coupled with the production of proinflammatory cytokines and antimicrobial peptides, this 
results in important consequences for lung host defense.  Additionally, the IL-17 signaling 
pathway may play an important role in airway hypersensitivity and other chronic lung diseases, 
including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). 
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As mentioned before, IL-17RA is ubiquitously expressed.  In the lung, IL-17RA 
expression has been described on the basolateral surfaces of well-differentiated airway epithelial 
cells, suggesting that these cells can serve as a target for IL-17 (272).  Mice lacking either IL-17 
or IL-17RA have demonstrated increases in susceptibility to Gram-negative bacteria, including 
Klebsiella pneumoniae (273) and Mycoplasma pneumoniae (274).  In the K. pneumoniae model, 
IL-17RA knockout mice showed a decrease in neutrophil response and higher bacterial burdens 
in the lung as well as more dissemination to the spleen.  All of this correlated with increased 
mortality (273).  IL23p19 deficient mice, which have decreased levels of IL-17 exhibit a similar 
phenotype.  In these mice, treatment with recombinant IL-17 restores the normal immune 
response and results in reduced bacterial burden (275).  Results in the M. pneumoniae model are 
similar: lower levels of IL-17 correlate with decreased neutrophil recruitment and higher 
bacterial burden (274). 
In contrast, reports suggest that IL-23 and IL-17 are dispensable for protection against 
primary Mycobacterium tuberculosis infection.  Loss of IL-17RA does not decrease clearance of 
M. tuberculosis (276).  On the other hand, IL-23 is induced by M. tuberculosis, and use of IL-23 
as a vaccine adjuvant in M. tuberculosis vaccination results in a more robust antigen-specific T 
cell response (262, 277, 278).  Use of IL-23, while decreasing mycobacterial burden, increases 
both Th1 cells and Th17 cells (277, 278).  It has further been demonstrated that γδ T cells are the 
dominant source of IL-17 in the tuberculosis model (220). 
Aside from the aforementioned report on Tc17 cells in the setting of influenza infection 
(160), there is little data on the role of IL-17 in host defense against viral pneumonias.  However, 
there is ample evidence that fungal host defense in the lung is also affected by IL-17 signaling.  
In a model of Pneumocystis carinii pneumonia (PCP), mice with reduced levels of IL-17 have 
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higher fungal burdens, suggesting a beneficial role for IL-17 in fungal clearance (279).  
However, in apparent contrast to this, decreases in IL-23 results in more efficient clearance of 
Aspergillus fumigatus.  Further studies suggested this was because IL-17 may actually inhibit 
fungicidal activity of neutrophils (280).  This apparent dichotomy in protective vs. detrimental 
roles of IL-17 in fungal clearance is reflected in other extrapulmonary models of fungal 
infection, including Candida albicans (protective role in intravenous infection, detrimental role 
in intragastric infection) (280-282) and Crytococcus neoformans (protective role) (283).  Further 
studies are needed to clarify the factors that determine whether IL-17 is protective or detrimental 
in the antifungal immune response. 
Further evidence for the role of IL-17 in host defense is apparent in Job’s syndrome (also 
known as hyper-IgE syndrome) patients.  These patients have a defect in STAT3, which is 
important in both IL-6 and IL-23 signaling, and therefore key to the polarization towards Th17 
cells (284).  As a result, there is a decrease in Th17 cells and IL-17 production in these patients 
(285, 286).  These patients come to medical attention with chronic, recurrent infections with 
Staphylococcus aureus,  Haemophilus influenzae, Streptococcus pneumoniae and other 
pathogens (284-286). 
Importantly, the neutrophil response is not the only mechanism by which IL-17 aids in 
host defense.  As mentioned previously, IL-17 results in the induction of several antimicrobial 
peptides.  These include β-defensins and S100 proteins (S100A7, S100A8, S100A9).  The 
expression of these antimicrobial peptides is enhanced by the synergistic expression of IL-17 and 
IL-22, another Th17 cytokine (266-271).  Like IL-17, IL-22 has been shown to play an important 
role in host defense against bacterial pneumonia as loss of IL-22 results in increased 
susceptibility to K. pneumoniae (268). 
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It is also important to note, however, that host defense is not the only role that IL-17 has 
in the lung.  IL-17 also plays a role in upregulating mucus production in the airway.  MUC5B 
and MUC5AC, two mucin proteins that constitute much of the mucus in respiratory secretions, 
are both inducible by IL-17 (271).  Several chronic lung diseases are characterized by 
hypersecretion of mucus, including CF, COPD, and asthma; therefore, it is important to 
understand what role, if any, IL-17 might play in these disease states. 
The role of IL-17 in allergic airway disease and asthma models is somewhat less clear 
than its role in host defense.  It had been widely thought that asthma was due to Th2 cytokine 
production driving an eosinophilic response in the airways, resulting in mucus hypersecretion, 
bronchoconstriction, and airway hyperresponsiveness.  This could be attenuated by the use of 
glucocorticoids (287, 288).  However, it has been suggested that there are also steroid-resistant 
forms of asthma which are mediated not by eosinophils, but by neutrophils (289).  Multiple 
studies have demonstrated that neutralization or loss of IL-17 reduces neutrophil recruitment to 
the lung in response to an OVA-induced asthma murine model (290-293).  However, some 
studies have shown no effect on eosinophil recruitment (291, 293) while others suggest that these 
mice also have lower numbers of eosinophils in the airways and lower serum IgE levels (290, 
292).  Interestingly, transfer of Th17 cells that have been polarized in vitro results in a 
neutrophilic inflammation of the airways in response to the OVA-induced asthma model, 
whereas transfer of Th2 cells results in an eosinophilic inflammation.  In both cases, the airways 
were hyperresponsive to methacholine challenge, but only the Th2 response was attenuated by 
glucocorticoid treatment (294).  This suggests that Th17 may play a role in the pathogenesis of 
steroid-resistant asthma.   
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CF is another serious, chronic inflammatory disease of the lung in which patients have an 
excess of mucus in the airway.  CF is attributed to mutations in an ion channel- cystic fibrosis 
transmembrane conductance regulator (CFTR)- that results in decreased amounts of airway 
surface liquid.  This in turn prevents normal function of cilia and the accumulation of mucus, 
which leads to recurrent pulmonary infections (reviewed in (295).  CF patients undergoing 
pulmonary exacerbations were found to have increases in IL-17 in their sputum.  These IL-17 
levels correlated with colonization by Pseudomonas aeruginosa, and declined with antibiotic 
treatment (255).  This suggests that IL-17 plays a role in host defense under chronic 
inflammatory conditions.  However, it has also been shown in vitro that IL-17 is capable of 
inducing bicarbonate secretion in human bronchial epithelial cells (296).  This may have 
important consequences in regulating the volume of the airway surface liquid, and combined 
with the ability of IL-17 to induce mucus production (271), suggests that IL-17 may play an 
important role in mucociliary clearance in both the CF and healthy lung. 
 
1.3.5 Roles of IL-17 Outside of the Lung 
 
Interleukin 17 has been studied in several settings outside of the lung.  Aside from roles in host 
defense, it has been shown to play a role in models of several autoimmune diseases, including 
psoriasis, rheumatoid arthritis, colitis, and experimental autoimmune encephalitis (EAE), a 
murine model of multiple sclerosis. 
Similar to the lung, IL-17 has been identified as playing a protective role in several other 
bacterial infection models.  Enteric Citrobacter rodentium infection is worsened in IL-23p19-
deficient mice (230).  Neutralization of IL-17 results in decreased clearance of Escherichia coli 
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following intraperitoneal infection (297).  IL-17RA knockouts are more susceptible to 
Porphyromonas gingivalis (298) and have higher bacterial burdens in both the spleen and liver 
following Salmonella enterica infection (299).  These receptor knockout mice, when challenged 
with Listeria monocytogenes do not demonstrate increased bacterial load in the spleen (268), but 
other studies have demonstrated that in the absence of IL-17, the bacterial burden in the liver is 
higher, and granuloma formation is impaired (300, 301).  This suggests that IL-17 may play a 
role in clearance from the liver but not in dissemination to, or clearance from, the spleen.  
Interestingly, in both the S. enterica and L. monocytogenes models, γδ T cells appear to be an 
important early cellular source of IL-17 (299, 300). 
As in the lung, there is little data available concerning IL-17’s role in other viral 
infections.  Virus-specific IL-17-producing CD4+ T cells have been detected early in HIV 
infection, but these cells disappeared throughout the duration of chronic infection.  Further, there 
was no correlation between the number of IL-17-producing cells and viral load (302).  In a 
vaccinia virus-infection model, IL-23 induced protection, and this protection was at least partly 
mitigated by neutralization of IL-17 (303).  In a corneal model of herpes simplex virus (HSV)-1 
infection, IL-17 is induced as early as 24 hours and persists at low levels.  Early in the infection, 
IL-17RA deficient mice display decreased neutrophil recruitment to the eye, and this correlates 
with decreased corneal opacity, a measure of tissue pathology.  However, this effect was 
temporary, as the receptor-deficient mice had similar levels of neutrophil recruitment and corneal 
pathology later in the infection (304). 
IL-17 has also been extensively studied in different autoimmune models.  In the EAE 
model of MS, it was initially believed that Th1 cells were responsible for the autoimmune 
pathology, though loss of Th1 cytokines (including IFN-γ and IL-12) did not affect disease 
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progression (305, 306).  It was later shown that IL-23, not IL-12, was responsible for 
development of EAE (307), leading to the view that Th17 cells were responsible for the 
pathology.  Indeed, adoptive transfer of Th17 cells resulted in the induction of autoimmunity 
(308, 309).  Adoptive transfer of myelin-specific T cells from IL-17 knockout mice resulted in 
milder disease, implicating the cytokine in disease pathogenesis (310).  However, a recent report 
has demonstrated that mice lacking either IL-17A or IL-17F (or both) are still susceptible to 
developing EAE.  Further, mice overexpressing IL-17A do not display a difference in disease 
development compared to wild type controls (311).  This suggests that while Th17 cells may be 
pathogenic, EAE is likely not entirely IL-17-dependent, but there are also contributions from IL-
17-independent mechanisms.  In support of this, others have shown that transfer of Th1 cells also 
results in disease, though the pathology is slightly different (namely, Th1-induced infiltrates 
were mainly macrophages whereas Th17 infiltrates were mainly neutrophils) (312, 313), again 
suggesting that disease development is not entirely dependent upon IL-17. 
Th17 cells, though perhaps not IL-17, may also be implicated in psoriasis, a chronic 
inflammatory skin disease.  Both IL-23 and IL-17 have been identified in psoriatic lesions (314, 
315).  T cells taken from the lesions and stimulated in vitro demonstrate an ability to produce IL-
17 (315).  However, levels of these cytokines in non-lesional skin or in the periphery are 
undetectable (316).  Further, no causative effect of IL-17 on the development of psoriasis was 
established.  Instead, reports identified the Th17 cytokine IL-22 as playing a role in the 
pathogenesis of the disease.  This may be due, in part, to the induction of tissue repair and wound 
healing genes in keratinocytes in response to IL-22.  Not only is IL-22 elevated in psoriatic 
lesions, it is also present in the serum of psoriatic patients, and these levels correlate with disease 
severity (317, 318).  A subsequent report has likewise identified IL-22, as well as IL-20, as a key 
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mediator of the epithelial changes seen in psoriasis, and that IL-17, while increasing levels of 
neutrophil-attracting chemokines, does not induce psoriatic changes in the epithelium (319). 
Th17 cells have also been shown to be involved in autoimmune arthritis.  IL-17 is found 
at higher levels in the joint spaces of rheumatoid arthritis (RA) than in healthy patients or in 
osteoarthritis patients (320).  Higher levels of IL-17 are predictive for worse disease outcomes 
(321).  There are multiple mechanisms by which IL-17 may play a role in disease pathogenesis.  
IL-17 synergizes with IL-1 to increase osteoclast differentiation, resulting in bone erosion (322).  
It has further been demonstrated that IL-17 upregulates production of matrix metalloproteinases 
(MMPs) by synovial fibroblasts, and that these MMPs are capable of directly breaking down 
cartilage (323).  This is in addition to IL-17’s role in recruiting both monocytes and neutrophils 
to the joint space (324, 325). 
In the gut, the IL-23-Th17 pathway has been implicated in not just host defense, but has 
been heavily studied in several models of colitis as well.  Because the gut is a site of bacterial 
colonization, IL-23 and IL-17 are constituitively expressed (326).  However, in multiple models 
of colitis there are increased levels of IL-23, IL-17, and RORγt (327-330).  Further, 
overexpression of IL-23p19 results in severe inflammation of the small and large intestine (as 
part of a systemic inflammatory phenotype) (331).  Additionally, transfer of Th17 cells from 
colitic mice into SCID mice leads to the development of colitis that is treatable by blocking IL-
23p19 (332).  However, like other diseases previously described, the role of IL-17 in colitis is 
not clearly defined.  Data from these same models of colitis have shown tissue inflammation and 
injury in the absence of IL-17 and T cells, suggesting that IL-23 has other effects in causing 
disease (333).  Perhaps even more contradictory, IL-17 neutralization increases the severity of 
dextran sodium sulfate (DSS)-induced colitis (334), whereas IL-17RA-deficient mice are 
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protected in a different model (atrinitrobenzenesulfonic acid (TNBS)-induced colitis) (335).  
Taken together, all of this suggests that regulation of the IL-23/IL-17 response in the gut is 
important in the development of colitis, though the exact role and mechanisms may not be fully 
understood. 
 
1.3.6 Interleukin-17: Summary 
 
IL-17 is a cytokine that plays a role in many disease states and organ systems.  The IL-17 
family consists of 6 members (IL-17A through IL-17F) that are capable of homo- or 
heterodimerizing.  Of these, IL-17A and IL-17F share the highest degree of homology, while IL-
17E (also known as IL-25) is the most disparate member of the family.  IL-17A and IL-17F are 
expressed mostly by activated T cells.  Indeed, a distinct subset of CD4+ T cells that produces 
IL-17A, IL-17F, and other cytokines including IL-22, has been characterized and termed Th17 
cells.  A recent report describes a similar subset of CD8+ T cells, referred to as Tc17 cells.  In 
addition to these subsets, IL-17 can also be produced by γδ T cells and NKT cells. 
Of the cellular sources of IL-17, Th17 cells have been characterized most extensively.  In 
murine models, these cells differentiate in the periphery in response to TGF-β, IL-6, and IL-1β.  
IL-23 supports the expansion and maintenance of these cells.  Aryl hydrocarbon receptor (AhR) 
has also been reported to play a role in polarization towards IL-17Differentiation requires 
STAT3 signaling and activation of the RORγt transcription factor.  In contrast to αβ CD4+ and 
CD8+, it has been reported that γδ T cells differentiate into IL-17 producers during thymic 
selection, allowing them to quickly produce IL-17 in the periphery upon stimulation. 
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IL-17A and IL-17F both signal through IL-17RA.  The receptor-ligand affinity is rather 
low, but recent studies have suggested an interaction between IL-17RA and IL-17RC which 
increases binding affinity, though the stoichiometry of these interactions are not known.  IL-
17RA signals via activation of NF-kB and ERK pathways.  This results in the induction of 
several genes, including proinflammatory cytokines, chemokines, and growth factors that 
promote granulopoeisis and neutrophil chemotaxis.  Additionally, IL-17 upregulates mucin 
expression as well as several acute phase proteins, and can synergize with IL-22 to upregulate 
production of several antimicrobial effector molecules. 
The IL-23/IL-17 signaling axis has been studied in multiple disease models.  This 
includes many autoimmune diseases, including psoriasis, rheumatoid arthritis, colitis, and the 
EAE model of multiple sclerosis.  In many of these models, the precise role of IL-17, or the 
mechanism by which it affects disease progression is not fully understood.  In the lung, IL-17 has 
been implicated in the pathogenesis of steroid-resistant asthma as well as other chronic 
inflammatory diseases, including CF.  IL-17 also plays a key role in host defense, primarily 
through recruitment of neutrophils and induction of antimicrobial peptides.  However, the effect 
of IL-17 on protection seems to depend on the infectious organism and model system being 
studied.  This perhaps emphasizes the point that IL-17 is but one part of a complex and intricate 
immune response, whether in an autoimmune or host defense role. 
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1.4 Statement of Hypothesis and Specific Aims 
 
It is well-established that one endpoint of IL-17 signaling is neutrophil production and 
recruitment.  This is important in the control of bacterial pneumonias, due to the antimicrobial 
properties of neutrophils.  However, the role of IL-17 signaling and neutrophil responses in the 
setting of viral pneumonias is not well established.  In the influenza model, neutrophils have 
been shown to exert some antiviral effects, including the production of reactive oxygen species 
and α-defensins.  Further, in highly pathogenic influenza models, depletion of neutrophils using 
anti-Gr1 results in decreased viral titers. 
Unfortunately, neutrophils have also been implicated in acute lung injury in response to a 
wide variety of insults.  This includes models of highly pathogenic influenza, in which there is an 
excessive neutrophil infiltration associated with increased lung injury.  We therefore have chosen 
to investigate the role of IL-17 signaling in a model of influenza pneumonia to identify its role in 
neutrophil recruitment and the effects on lung injury and viral clearance.  We hypothesized that 
interrupting IL-17 signaling would result in decreased neutrophil recruitment to the 
airway, associated with decreased damage to the lung, and with minimal effects on viral 
clearance. 
Aim 1: Identify and describe the phenotype of IL-17RA-/- mice in response to 
challenge with influenza A.  IL-17RA-/- and wild-type control mice are to be challenged with a 
lethal dose of influenza A/PR/8/34 (H1N1).  Outcome measures will include morbidity and 
mortality, viral burden, lung histopathology, neutrophil recruitment in the BALF, 
proinflammatory cytokine production, and lung injury as measured by total protein and LDH in 
the BALF.  We hypothesize that the IL-17RA-/- mice will have less lung injury, less 
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inflammation, and lower levels of proinflammatory cytokines, resulting in decreased morbidity 
and mortality.  We further expect minimal differences in viral clearance. 
Aim 2: Determine the role(s) that neutrophils, CD8+ T cells, and proinflammatory 
cytokines may play in the phenotype described in Aim 1.  To assess potential mechanisms for 
differences in lung injury and/or viral clearance, we propose to examine three aspects of the 
immune response: CD8+ T cell recruitment, differences in cytokine production- especially TNF-
α and IL-6, and differences in neutrophil recruitment and oxidative damage to the lung. 
Aim 3: Identify the time course and cellular source of IL-17 production in response 
to influenza.  The time course of IL-17 production will be measured at the level of mRNA by 
semi-quantitative real time PCR and at the protein level by ELISA.  The cellular source of IL-17 
production will be determined by ELISpot, intracellular cytokine staining, and use of IL-17A-
GFP reporter mice. 
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2.0 CRITICAL ROLE OF IL-17RA SIGNALING IN THE 
IMMUNOPATHOLOGY OF INFLUENZA INFECTION 
 
 
2.1 ABSTRACT 
 
Acute lung injury due to influenza infection is associated with high mortality, an increase in 
neutrophils in the airspace, and increases in tissue myeloperoxidase (MPO).  Because IL-17A 
and IL-17F, ligands for IL-17RA, have been shown to mediate neutrophil emigration into the 
lung in response to LPS or gram negative bacterial pneumonia, we hypothesized that IL-17RA 
signaling was critical for acute lung injury in response to pulmonary influenza infection.  IL-
17RA was critical for weight loss and both neutrophil migration and increases in tissue MPO 
after influenza infection.  However IL-17RA was dispensable for the recruitment of CD8+ T-
cells specific for influenza hemagglutinin or nucleoprotein.  Consistent with this, IL-17RA was 
not required for viral clearance.  However, in the setting of influenza infection, IL-17RA-/- mice 
showed significantly reduced levels of oxidized phospholipids, which have previously been 
shown to be an important mediator in several models of acute lung injury, including influenza 
infection and gastric acid aspiration.  Taken together, these data support targeting IL-17 or IL-
17RA in acute lung injury due to acute viral infection.   
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2.2 INTRODUCTION 
 
Acute lung injury (ALI) is a severe clinical state, characterized by non-cardiogenic pulmonary 
edema, capillary leak, and hypoxemia.  It can be triggered by both infectious and non-infectious 
stimuli.  The most severe form of ALI is acute respiratory distress syndrome (ARDS)(51).  Most 
patients who died in the severe acute respiratory syndrome (SARS) virus outbreak in 2003 
developed ARDS (26).  Likewise, the Spanish influenza pandemic of 1918 and current outbreaks 
of H5N1 influenza have both been documented to cause ARDS in mice and primates (27, 36, 39, 
189).  Neutrophils play an important part in the pathogenesis of ALI, as they rapidly infiltrate the 
lung and serve as an important source of proinflammatory cytokines such as interleukin (IL)-1β 
and tumor necrosis factor (TNF)-α as well as reactive oxygen intermediates (ROI) (56, 336-338). 
Recent studies have shown that oxidized phospholipids have many pro-inflammatory 
properties (339) and are an important signal in the development of ALI.  Upon oxidation, airway 
phospholipids are capable of signaling through Toll-like receptor (TLR) 4.  This signal is 
MyD88-independent and involves the TRIF-TRAF6 signaling pathway, and blocking this signal 
can prevent ALI.  This role for oxidized phospholipids in the pathogenesis of ALI has been 
shown for both infectious (influenza) and non-infectious (acid aspiration) models (59).  Given 
the ability of neutrophils to generate ROI’s, it is possible that these cells are responsible for the 
oxidation of airway phospholipids. 
The role of neutrophils in severe influenza infections has been debated.  Studies using the 
reconstructed 1918 virus show that highly virulent strains of influenza result in an overwhelming 
neutrophilic infiltrate that is associated with worsening lung injury (36, 38, 39).  However, 
neutrophils have also been shown to play a role in control and clearance of influenza virus in 
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experimental models (125, 126, 340-342), and neutrophil depletion resulted in an uncontrolled 
and ultimately lethal viremia in the reconstructed 1918 influenza model (38).  It is important to 
note, though, that neutrophil depletion using the monoclonal antibody RB6-8C5 is complicated 
by the concurrent depletion of other monocytes, dendritic cells, and even some CD8+ T cells 
(343-345). 
IL-17 is a potent regulator of the neutrophil response.  Both IL-17A and IL-17F are 
capable of signaling through the IL-17 receptor A (IL-17RA) to induce granulopoetic factors 
such as granulocyte-colony-stimulating factor (G-CSF) and stem cell factor (SCF) which leads to 
expansion of neutrophil progenitors in the bone marrow and spleen, as well as expansion of 
mature neutrophils in peripheral blood (346, 347).  Further, IL-17RA signaling upregulates 
production of neutrophilic-chemokines such as CXCL1, CXCL2, CXCL5, CXCL6, and CXCL8, 
which in turn regulate neutrophil emigration to mucosal sites (260, 348, 349).  Due to this role in 
neutrophil expansion and recruitment, IL-17RA signaling is an important part of the host 
response to extracellular bacterial infections.  It has previously been demonstrated that defects in 
the IL-17 axis results in a decreased neutrophil response associated with higher bacterial burdens 
and decreased survival when mice are challenged with the gram negative bacterium K. 
pneumoniae (273, 348). 
Given IL-17RA’s critical role in neutrophil recruitment and the ability of neutrophils to 
generate ROI’s, along with the important role oxidized phospholipids play in the pathogenesis of 
ALI, we wanted to determine if blocking IL-17RA signaling conferred protection against lung 
injury associated with influenza infection.  Using an acute infection model- influenza A/PR/8/34 
(H1N1) (PR/8)- we sought to identify a pathway by which the neutrophilic infiltrate is able to be 
regulated in order to reduce lung injury. 
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 2.3 METHODS 
 
2.3.1 Animal Infections and HCl Challenge 
 
IL-17ra on a BALB/cJ background (350) and B6 background (348), and p55/p75 on a B6.129 
background (351), have been previously described.  Wild-type controls included BALB/cJ, 
B6.129, and C57BL6 mice.  Mice were challenged intranasally with an LD90 of influenza 
A/PR/8/34 (H1N1) in phosphate-buffered saline (PBS).  Following infection, mice were 
monitored daily for weight loss and signs of clinical illness (352).  Mice were sacrificed at 
indicated time points.  For HCl challenge, mice were given 100 μL of HCl (pH 1.5) 
intratracheally and sacrificed at 24 hours post-challenge (353).  Control mice received equivalent 
volumes of PBS. 
 
2.3.2 Lung harvest and bronchoalveolar lavage 
 
At indicated time points, mice were euthanized with an overdose of inhaled isofluorane.  The 
abdomen was opened and the animals were exsanguinated by cutting of the renal artery.  The 
trachea was then exposed and cannulated.  1 mL of sterile PBS was injected into the airway and 
then collected.  Animals were then perfused with PBS via injection in the right ventricle to flush 
blood vessels in the lung.  Left lungs were collected in TRIzol reagent (InVitrogen) and 
homogenized using an electric tissue grinder.  RNA was purified according to manufacturer’s 
instructions.  Right lungs were collected and homogenized in PBS for use in plaque assays and 
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ELISA.   Lavage fluid was spun down at 500 x g for 5 minutes to pellet cells.  BAL cells were 
counted using a Coulter Counter (Beckton-Dickinson) and 105 cells were spun onto a glass slide, 
then fixed and stained for counting.   
 
2.3.3  IL-6 neutralization studies 
 
A monoclonal antibody capable of neutralizing IL-6 (clone MP5-20F3) was administered to mice 
via intravenous injection at a concentration of 3 μg/g of body weight at the time of influenza 
challenge (354).  A second dose was administered at 3 dpi.  Mice were monitored daily and 
sacrificed at 6 dpi.  To ensure sufficient neutralizing antibody was delivered, lung homogenates 
were used in a direct ELISA.  Briefly, 96 well ELISA plates were coated with 100 ng of 
recombinant IL-6 at room temperature for 4 hours.  Plates were washed 4x, blocked overnight 
with 1% bovine serum albumin (BSA) at 4 degrees Celsius, then washed 4x again.  100 μL of 
lung homogenates were added per well, incubated for 2 h at room temp, then washed 4x, 
followed by detection with α-IgG1-HRP.  Plates were developed using TMB substrate reagents 
(BD). 
 
2.3.4 Real time PCR 
 
RNA collected from the left lung was used as template to generate cDNA using iScript reagents 
and protocol (BioRad).  cDNA was then used in fast real-time PCR using the Applied 
Biosystems 7900HT.  Reaction conditions were 95° Celsius for 1 second and 60 degrees for 20 
seconds, repeated for 40 cycles, with a 20 second hot start at 95° C.  Primer and probe sequences 
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were as follows: Influenza M Protein Forward- 5’-GGA CTG CAG CGT AGA CGC TT-3’, 
Influenza M Protein Reverse- 5’-CAT CCT GTT GTA TAT GAG GCC CAT-3’, Influenza M 
Protein Probe- 5’-CTC AGT TAT TCT GCT GGT GCA CTT GCC A-3’.  18s RNA was used as 
a housekeeping gene with the following primer/probe sequences: Forward- 5’-GAT CCA TTG 
GAG GGC AAG TCT-3’, Reverse- 5’- GCA GCA ACT TTA ATA TAC GCT ATT GC-3’, 
Probe- 5’-TGC CAG CAG CCG CGG TAA TTC-3’.  Fold-change in mRNA was quantified 
using the ΔΔCT method. 
 
2.3.5 Measurement of cytokines 
 
IL-17A and IL-17F in lung homogenate were measured by ELISA (R&D DuoSet) according to 
manufacturer’s instructions.  All other cytokines were measured by multiplex analysis using 
Millinex (Millipore) reagents according to manufacturer’s instructions and analyzed on the 
Bioplex reader (BioRad). 
 
2.3.6 Assessment of lung injury 
 
Total protein in the BALF was measured using the BCA Protein Assay Kit (Pierce).  LDH 
activity was measured using the lactate dehydrogenase assay (Sigma).  Both assays were 
performed in a 96 well plate for 30 minutes according to manufacturer’s instructions and 
analyzed using the Benchmark Plus plate reader (BioRad). 
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2.3.7 Lung fixation and histologic examination 
 
Animals were sacrificed at the indicated time points, the trachea was exposed and 
cannulated.  Lungs were inflated with 10% neutral buffered formalin (Sigma) for 10-15 minutes, 
removed from the animal and placed in fresh 10% neutral buffered formalin for at least 24 hours 
at 4° Celsius before processing and embedding.  Sections were cut (5μm) and stained with 
Hematoxylin and Eosin (H&E) for histopathologic evaluation (355).  
Slides were blinded and scored in a semiquantitative manner according to the relative 
degree of inflammatory infiltration (356).  Inflammation was scored as follows: 0= no 
inflammation, 1= perivascular cuff of inflammatory cells, 2= mild inflammation, extending 
throughout <25% of the lung, 3= moderate inflammation covering 25-50% of the lung, 4= severe 
inflammation involving over half of the lung. 
 
2.3.8 Measurement of oxidized phospholipids 
 
Oxidized phospholipids were detected by direct ELISA.  Briefly, BALF was adsorbed 
onto 96-well ELISA plates, normalized for 100 ng total protein per well, overnight at 4 degrees 
Celsius.  Plates were washed 4x with PBS + 0.5% Tween-20 before blocking with 1% BSA for 1 
h at room temperature.  Plates were then washed 4x again and probed with 100 μL of the 
monoclonal antibody EO6 (a generous gift of J.L. Witztum) (357), diluted to 5 μg/mL in PBS.  
Plates were incubated for 2 h at room temperature, then washed 4x.  Anti-IgM conjugated to 
HRP (Southern Biotech) was used as a secondary antibody, diluted 1:2,000, for 2 h at room 
temperature.  Plates were washed one more time before being developed with TMB substrate 
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reagents (BD).  Absorbance was read at 450nm, with a wavelength correction at 540nm 
subtracted out. 
 
2.3.9 Plaque assay 
 
Influenza titers were measured by traditional plaque assay (358).  Briefly, lungs were 
homogenized and homogenates were diluted before being applied to 95% confluent MDCK 
cells.  Virus was adsorbed onto the cells for 1hr at room temperature before being washed off 4x 
with serum-free DMEM.  Cells were then covered with serum-free DMEM containing trypsin 
and 0.8% agarose and incubated for 48h at 37° Celsius with 5% carbon dioxide.  Agarose was 
then removed and the monolayer was stained with 1% Genetian Violet to allow for the 
visualization and counting of plaques.   
 
2.3.10 Depletion of neutrophils 
 
Depletion of neutrophils was accomplished by the administration of monoclonal antibodies RB6-
8C5 (anti-Gr1, R&D) (342) or 1A8 (anti-Ly6G, BioXCell) (359) where indicated.  Antibodies 
were given by intraperitoneal injection 24 hours prior to challenge, and every 48 hours thereafter.  
Both antibodies were given at a dosage of 0.3mg per animal.  Neutrophil depletion was 
confirmed by analysis of peripheral blood smears at the time of challenge. 
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2.3.11 Statistics 
 
All data is presented as the mean ± s.e.m.  Significance was tested using unpaired t-tests, 
ANOVA, or, in the case of survival curves, Kaplan-Meier analysis.  All statistics were analyzed 
using GraphPad Prism 4 software. 
 
 
2.4  RESULTS 
 
2.4.1 Decreased Morbidity and Mortality among IL-17RA knockout mice 
 
To examine the effects of IL-17 signaling during influenza infection, we challenged IL-17RA 
knockout mice on a BALB/cJ background (350) and BALB/cJ controls with 100 pfu of PR/8.  
Following viral challenge, we noted that the IL-17RA-deficient mice experienced less weight 
loss throughout the course of infection (Figure 1A).  This correlated well with higher survival 
rates among the knockout mice (Figure 1B), suggesting that IL-17RA signaling may be 
detrimental in the response to influenza virus challenge.  It is important to note that the 
differences in weight loss were significant from days 2 through 8, beyond which the data is 
subject to survival bias.  To rule out the possibility that the morbidity and morality differences 
that we observed were due to differences in viral clearance, we measured viral burden by real-
time PCR, using primers and probe for the influenza M1 gene.  Somewhat surprisingly, we found 
that despite their decrease in morbidity and mortality, the IL-17RA knockout mice had a trend 
toward a higher viral burden at 6 dpi (Figure 1C).  This data trend was also supported by plaque  
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Figure 1: Weight loss, mortality, and viral burden following challenge with influenza A/PR/8 IL-
17RA-/- mice exhibit less weight loss (A) and mortality (B) following viral challenge (n=10/group).  Mice 
were monitored daily for weight loss and clinical signs of illness.  Viral burden was determined by 
quantitative PCR (C) for the influenza M1 protein (n=4/group/time point), or by viral plaque assay (D). 
*p<0.05, **p=0.0067, ***p=0.0093 
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assay (Figure 1D).  Taken together, these data show that despite a trend toward higher viral 
burdens, IL-17RA knockout mice are able to better tolerate influenza challenge, as they 
ultimately clear the virus and recover from the challenge.  This suggests that these mice may 
have decreased immunopathology that would explain the observed phenotype. 
  
2.4.2 IL-17RA knockout mice have lower levels of inflammation 
 
Histological examination of lungs at 6 dpi showed dramatic decreases in inflammation among 
the IL-17RA knockout mice (Figures 2A and B).  Lungs were scored on the basis of the degree 
and extent of inflammation (356).  By day 2, both the wild-type and knockout mice exhibit 
limited inflammation, mainly restricted to the perivascular areas (Figure 2C).  However, by day 
6, wild-type mice showed heavy perivascular inflammatory infiltrates, with inflammation 
extending out into the parenchyma (Figures 2A and 2C).  In contrast, the IL-17RA knockout 
mice had only mild inflammation mainly limited to the perivascular bed, with the lung 
parenchyma relatively unaffected (Figures 2B and 2C). 
Given these histological findings, we sought to measure the levels of inflammatory 
cytokines in lung homogenates.  TNF-α (Figure 3A) and IL-1β (Figure 3B), both of which can 
be produced by neutrophils in ALI (337), were observed to be lower in IL-17RA/- mice.  
Additionally, IL-6 was greatly reduced in the IL-17RA knockout mice compared to wild-type 
controls (Figure 3C).  Furthermore, levels of the IL-17-responsive chemokines and cytokines, 
including CXCL1 (KC) and G-CSF (Figures 3D and E) were lower in the IL-17RA knockout 
mice, as would be expected.  Interestingly, there was a decrease in IFN-γ at 6 dpi among the IL- 
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Figure 2: Differences in inflammation following influenza challenge  BALB/c (A) and IL-17RA -/- (B) 
lungs harvested at 6 dpi.  Inflated with 10% formalin, paraffin-embedded, and H&E stained.  Calibration 
bar is 100um.  Pathology scored (C) as follows: 0= no inflammation, 1= perivascular cuff of inflammatory 
cells, 2= mild inflammation, extending throughout <25% of the lung, 3= moderate inflammation covering 
25-50% of the lung, 4= severe inflammation involving over half of the lung.  *p=0.004 
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 17RA knockout mice (Figure 3F).  These cytokine data support the histological findings of less 
inflammation in the IL-17RA-deficient mice. 
We next sought to determine if this decrease in inflammation resulted in lower levels of 
lung injury.  Measurement of total protein in the bronchoalveolar lavage fluid (BALF) suggests 
decreased capillary leak in the IL-17RA knockout mice (Figure 4A).  Moreover, consistent with 
less lung injury, levels of lactate dehydrogenase in the BALF was significantly lower in IL-
17RA knockout mice (Figure 4B).  In the context of lower levels of inflammation, these data 
suggest that the protection seen in the IL-17RA knockout mice may be due to lower levels of 
immunopathology.  
 
2.4.3  Protection is independent of ΤΝF−α and IL-6 
 
Previously published studies have identified a role for TNF-α in the pulmonary 
immunopathology caused by influenaza infection, as mice lacking TNF receptors (p55 and p75) 
had decreased mortality and weight loss (161, 162).  Because we observed a decrease in TNF-α 
levels in our knockout mice, we sought to determine if reduced TNF production was responsible 
for the protective phenotype we observed in IL-17RA -/- mice.  To investigate this, TNF receptor 
p55/p75 double knockout mice (351) were challenged with an LD90 of PR/8.  These mice are 
commercially available, but have only been backcrossed four times; therefore, B6.129 mice were 
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Figure 3: Cytokine response to influenza challenge.  Cytokines measured at 2 and 6 days 
post-infection.  BALB/c (white bars) vs. IL-17RA -/- (black bars)  *p<0.05 (n=4/group/timepoint)  (A). TNF-
α  (B). IL-1β  (C). IL-6  (D). KC  (E). G-CSF  (F). IFN-γ 
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Figure 4: Markers of Lung Injury.  Total protein (A) and LDH activity (B) in the bronchioalveolar lavage 
fluid.  White bars represent BALB/c mice, black bars show IL-17RA -/- mice. *p=0.01, **p=0.01 
(n=4/group/timepoint).  
 
used as controls.  Additionally, we infected IL-17RA-/- mice on a C57/B6 background (348) 
along with wild-type controls to demonstrate that the phenotype described was not strain-
specific.  In contrast to the IL-17RA -/- mice, TNF receptor p55/p75 double knockout mice 
showed significant weight loss which was similar to wild-type mice (Figure 5A).  Moreover, in 
contrast to IL-17RA-/- mice, TNF receptor p55/p75 double knockout mice had similar levels of 
total protein in the BALF (Figure 5B), compared to wild-type control mice.  Additionally, levels 
of LDH were unchanged (Figure 5C).  This suggests that the phenotype observed in the IL-17RA 
knockout mice is independent of TNFR signaling.  It is also important to note that G-CSF was 
unchanged (Figure 5D) and KC was even elevated in the double knockouts (Figure 5E), 
indicating that the reductions in these growth factors and chemokines among IL-17RA-/- mice 
was not TNF-dependent.  
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Figure 5: Protection is not dependent on TNF-α (A) Weight loss among B6.129 and p55/p75 
(n=6/group) following influenza challenge.  For comparison, IL-17RA-/- on C57/BL6 background and wild-
type controls (n=4/group) are also provided (B) Lung injury assessed by total protein in the BALF on day 
6.  (C) LDH activity in the BALF at 6 dpi was unchanged compared to wild-type controls (D).  Levels of G-
CSF were unchanged, and (E) levels of KC were elevated in the lung homogenate at 6 dpi. *p<0.05 
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Figure 6: Protection is not dependent on IL-6 (A) Weight loss among mice treated with an IL-6 
neutralizing antibody or isotype control (n=6/group) following influenza challenge.  Lung injury assessed 
by total protein in the BALF (B) and LDH activity in the BALF(C) on day 6 was unchanged compared to 
isotype controls.  Levels of G-CSF (D) and KC (E) were unchanged.  Levels of IL-6 (F) were drastically 
reduced by antibody neutralization, and an excess of anti-IL-6 in the lung (G) confirms that a sufficient 
amount of neutralizing antibody was present.  *p<0.001 
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 Similarly, we chose to test if the decrease in IL-6 levels in the IL-17RA mice was 
responsible for the protective phenotype.  Anti-IL-6 or control IgG was administered to BALB/c 
mice at the time of influenza challenge and again at 3 dpi.  The anti-IL-6 treated mice showed no 
differences in weight loss compared to controls (Figure 6A), nor did they show any differences 
in total protein in the BALF at 6 dpi (Figure 6B).  Likewise, levels of LDH were unchanged 
(Figure 6C).  There were no differences in G-CSF or KC after IL-6 neutralization (Figure 6D and 
E), illustrating that production of these proteins are also independent of IL-6.  To confirm the 
effectiveness of IL-6 antibody neutralization, IL-6 was measured in lung homogenate at 6 dpi 
and found to be drastically reduced (Figure 6F).  Additionally, free anti-IL-6 was measured in 
the lung homogenates, and it was found that free concentrations of neutralizing antibody were 
present in excess of IL-6 (Figure 6G), implying that the dosage of antibody was sufficient.  
These data indicate that the decrease in IL-6 levels observed in the IL-17RA knockout mice is 
not responsible for the reduced cachexia. 
 
2.4.4 IL-17RA-/- mice have reduced neutrophil migration and lipid oxidation 
 
IL-17 is responsible for the induction of several granulopoetic factors and chemokines that can 
result in an influx of neutrophils (260, 348).  Examination of the cells recovered in the BALF 
demonstrated that the IL-17RA knockout mice had a dramatic reduction in the number of 
neutrophils recruited to the airway (Figure 7A).  In contrast,   BAL macrophages and 
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Figure 7: Differences in cell recruitment to the airway.  IL-17RA-/- mice (black bars) show decreases 
in the number of neutrophils (A.) in the BAL compared to BALB/c controls (white bars), but no differences 
in macrophages (B.) or lymphocytes (C.) (n=4/group/timepoint).  Pentamer staining at 10 dpi show that 
there is no difference in the numbers of NP-specific (D.) or HA-specific (E.) CD8+ T cells (n=4/group) 
*p=0.03   
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lymphocytes were not significantly reduced (Figures 7B and 7C).  Further, examination of the 
hemagglutinin- and nucleoprotein-specific CD8+ T cell population revealed no differences at 10 
dpi, indicating that the recruitment of these cells is unaffected in the IL-17RA knockout animals 
(Figures 7D and E).  At 6 dpi, there were also no differences in the nucleoprotein-specific CD8+ 
T cells (BALB/c: 8.6x104 ± 1.0x104, IL-17RA-/-: 6.9x104 ± 1.5x104), and hemagglutinin-
specific cells were not detected. 
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Figure 8: Differences in oxidative stress.  Myeloperoxidase activity is decreased in the lung 
homogenates, and trends lower in the BALF, of the IL-17RA-/- mice compared to wild-type controls 
(n=5/group/timepoint).*p=0.03, **p=0.01 (A). Levels of oxidized phospholipids- capable of signaling 
through TLR4 to induce acute lung injury- as measured by ELISA, are lower in IL-17RA-/- mice than 
BALB/c controls (B.). (n=5/group/timepoint) ***p=0.02   
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Excessive neutrophil recruitment has been demonstrated in models of severe influenza 
infections, including H5N1 and a reconstructed 1918 virus, and is associated with worse 
immunopathology (36, 38).  Because of this, we chose to study the differences in neutrophils 
more closely.  Myeloperoxidase (MPO) activity, an enzyme found most abundantly in 
neutrophils and responsible for generating reactive oxygen species that can lead to oxidative 
damage (360), was decreased in lung homogenates of the IL-17RA- deficient mice when 
compared to BALB/c controls.  Further, MPO activity trended to be lower in the BALF cell 
pellets of these animals as well (Figure 8A).  Based on these findings and the established role of 
oxidized phospholipids in the pathogenesis of acute lung injury (59), we hypothesized that the 
IL-17RA-/- mice might be accumulating fewer oxidized phospholipids, which would in turn 
explain the decrease in lung injury seen in these mice during influenza infection. 
To measure oxidized phospholipids, we adsorbed BALF onto 96-well ELISA plates 
normalized for the amount of protein in the sample.  We then probed with EO6, a monoclonal  
antibody that specifically recognizes the phosphocholine head of phospholipids that contain an 
oxidized sn2 side chain, but does not recognize nonoxidized phospholipids (357).  It has been 
previously demonstrated that oxidized phospholipids that are recognized by EO6 are pro-
inflammatory (361).  We found that the IL-17RA knockout mice had significantly decreased 
levels of oxidized phospholipids (Figure 8B) in BAL fluid compared to wild-type mice at 6 dpi.  
To confirm the role of neutrophils in generating the oxidized phospholipids, we used an 
anti-Ly6G antibody (clone 1A8) to deplete neutrophils.  In contrast to the anti-Gr1 antibody 
(RB6-8C5) which recognizes both Ly6G and Ly6C, clone 1A8 reduces neutrophils but not Gr1+ 
monocytes (359).  This antibody was given by intraperitoneal injection every 48 hours, starting 
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Figure 9: Depletion of neutrophils decreases oxidized phospholipids and promotes survival 
Administration of monoclonal antibody 1A8 results in depletion of neutrophils, reflected by decreased 
neutrophils in the BALF (A.).  Mice receiving 1A8 also exhibited a decrease in the amount of oxidized 
phospholipids in the BALF (B.)  Administration of 1A8 also conferred a survival benefit (C.). *p<0.001, 
**p=0.01, ***p=0.04 
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 24 hours prior to influenza challenge.  Neutrophil depletion was confirmed by analysis of 
peripheral blood smears at the time of influenza challenge (data not shown).  At day 6, mice  
receiving 1A8 exhibited a paucity of neutrophils in the BALF (Figure 9A), as would be 
expected.  Furthermore, these mice demonstrated decreased levels of oxidized phospholipids in 
the BALF compared to mice receiving isotype control antibody (Figure 9B), suggesting that the 
difference in neutrophil recruitment in the IL-17RA-/- mice is sufficient to explain the decrease 
in oxidized phospholipids in that model.  Most importantly, the mice receiving anti-Ly6G 
exhibited a survival advantage compared to the isotype control group (Figure 9C).  This is in 
apparent contrast to other studies which have shown a detrimental effect to depleting neutrophils 
during an influenza challenge (38, 341, 342).  The reason for this difference may be due to 
differences in antibody specificity, as the other studies used RB6-8C5, thereby depleting other 
Gr1+ cells. 
Because oxidized phospholipids have previously been shown to play a critical role in 
acute lung injury in both acute viral infections as well as in acid aspiration, we investigated if IL-
17RA signaling was also critical for the generation of oxidized phospholipids and lung injury in 
acid aspiration.  To test this hypothesis, we chose to examine a model of aspiration pneumonia 
wherein hydrochloric acid is instilled into the airway.  Following HCl challenge in the airway, 
IL-17RA-/- mice had a significant decrease in neutrophil influx at 24 h post-challenge (Figure 
10A) as well as a decrease in the amount of oxidized phospholipids (Figure 10B) in BAL fluid. 
We next decided to specifically test the role of neutrophils in lipid oxidation and lung 
injury by depleting neutrophils in the HCl aspiration model using anti-Gr1.  As stated above,  
anti- Gr1 has been shown to also deplete a subpopulation of dendritic cells as well as CD8+ T 
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Figure 10: Decrease in neutrophils and oxidized phospholipids in response to HCl.  BALB/c mice 
were treated either anti-Gr1 (n=4) or control IgG (n=4).  These mice, plus IL-17RA-/- mice (n=4) were 
then challenged 24 hours later with 100uL of HCl (pH 1.5) and lavaged at 24 hours after challenge to 
assess (A). neutrophil recruitment and (B). levels of oxidized phospholipids in the BALF.  *p=0.006, 
**p=0.01 
 
cells (344, 345), making it difficult to interpret data in the influenza model; however due to the 
short time course of HCl model, depletion of other subsets would less likely play a role apart 
from depletion of neutrophils.  Administration of anti-Gr1 24 h prior to HCl challenge resulted in 
a highly significant decrease in neutrophils in the BALF at 24 h post-challenge similar to the IL-
17RA knockout mice (Figure 10A).  Importantly, anti-Gr1 also resulted in a significant decrease 
in the level of oxidized phospholipids in the BALF (Figure 10B), indicating that neutrophils are 
important in generating oxidized phospholipids, and that the decrease in neutrophils in our model 
is sufficient to explain the decrease in the accumulation of oxidized phospholipids in the airways. 
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2.5 DISCUSSION 
 
The data presented in this report provides support for the concept that IL-17RA signaling 
plays a key role in the process of lung injury.  We observed that IL-17RA knockout mice 
recruited fewer neutrophils to the airway in response to challenge with either influenza A virus 
or hydrochloric acid, and that this decrease in neutrophils results in lower amounts of oxidized 
phospholipids.  Others have previously shown that oxidized phospholipids play a key role in 
acute lung injury by serving as an endogenous ligand for TLR 4 and signaling through the TRIF-
TRAF6 pathway (59).  Our data shows that IL-17RA signaling regulates the amount of oxidized 
phospholipids in the airway, likely by regulating tissue burdens of neutrophils, which are critical 
sources of reactive oxygen species. 
IL-17RA-deficient mice are more susceptible to certain extracellular bacterial infections 
of the lung (273, 274), in part due to defective neutrophil migration into the lung.  However, the 
role of IL-17RA in primary pulmonary influenza host response has not been evaluated.  As IL-17 
has been shown to regulate ligands for CXCR2 such as KC and LIX (critical for neutrophil 
recruitment) as well as the ligands for CXCR3, MIG and IP-10 (important for Th1 cell 
recruitment) (262), it was important to determine if IL-17RA signaling was critical for viral 
clearance and virus specific CD8+ T-cell recruitment.  Additionally, CD8+ T cells are a 
contributor to lung damage in response to influenza challenge (362, 363).    Although IL-17RA-
/- mice showed a trend towards higher viral burdens on day 6, these mice ultimately cleared the 
virus and recovered.   Consistent with these findings, there was no significant differences in 
recruitment of virus specific CD8+ T-cells either for nucleoprotein on day 6 or 10 or 
hemagglutinin on day 10.  For these latter experiments, it was necessary to challenge mice with a 
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sublethal dose (so as to avoid survival bias) and examine the antigen-specific population at 10 
dpi since CD8+ T cells do not peak until 10 dpi. 
The slightly higher viral titers in the IL-17RA-/- mice was not unexpected, as it has 
previously been shown that neutrophil depletion has a deleterious effect on clearance of 
influenza (38, 341, 342).  However, this seemed to be in apparent conflict with the fact that they 
had decreased morbidity and mortality.  This can be explained by studies that have demonstrated 
that during highly virulent influenza infections, excessive neutrophil infiltrates were associated 
with more immunopathology (38).  This led us to investigate differences in inflammation and 
lung damage as a mechanism for the survival phenotype we observed.   
We observed that the IL-17RA knockout mice did indeed have less lung injury, as 
indicated by less total protein and LDH activity in the BALF.  Upon histological examination, it 
was apparent that the IL-17RA knockout mice had a dramatic decrease in the amount of 
inflammation in the lung.  This correlated well with decreases in many inflammatory cytokines.  
Importantly, three pro-inflammatory cytokines that are generally elevated in severe influenza 
infection as part of a cytokine storm, TNF-α , IL-1β , and IL-6 (36, 364), all either trended lower 
or were significantly reduced.  One potential explanation for the reduced levels of TNF-α and 
IL-1β is that neutrophils are a source of both TNF-α and IL-1β (336, 337, 365).   Because the 
cytokine storm has been hypothesized to play a role in the immunopathology of the more 
virulent influenza infections, and the fact that in certain models of arthritis, IL-17 has a TNF-α− 
and IL-1β− independent role in tissue inflammation (366, 367), we chose to examine whether 
TNF-α or  IL-6 could account for the reduced lung injury and cachexia we observed in IL-17RA 
knockout mice.   
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Neutralization of IL-6 or genetic ablation of  TNF p55/p75  receptor signaling failed to 
reduce acute lung injury or cachexia associated with influenza infection, demonstrating that the 
reduced lung injury in IL-17RA -/- mice is independent of the differences observed in the levels 
of these cytokines.  The lack of a role for TNFR signaling is in apparent contrast to experiments 
that have previously shown that immunopathology is driven by TNF signaling (161, 162).  This 
may be due to differences in our viral infection model compared to transgenic models used in the 
other reports.  Regardless, or data suggests that the differences in immunopathology that we 
observed in IL-17RA-/- mice were not due to the decreases in TNF-α or IL-6.    
Having eliminated the possibility of a decreased cytokine storm and decreased CD8+ T 
cells as causes of the protection, we next investigated the differences in neutrophil recruitment.  
IL-17 plays a key role in neutrophil proliferation and migration, primarily by induction of 
granulopoietic factors and chemokines (260, 346-349, 368).  Further, it has been demonstrated 
that genetic ablation of CXCR2 results in decreased neutrophil migration to the lung in response 
to influenza (369), and IL-17 is responsible for the regulation of some CXCR2 ligands (348).  
Consistent with this, we observed reduced lung neutrophils following influenza infection in the 
IL-17RA knockout mice.  Considering the mechanisms by which neutrophils are capable of 
causing tissue damage, one likely mechanism of lung injury is through the generation of reactive 
oxygen species and specifically, the oxidation of phospholipids (59).   
In support of that hypothesis, we found reduced MPO activity in both the BAL cell pellet 
and lung homogenate in IL-17RA knockout mice as well as a significantly lower level of 
oxidized phospholipids in the BALF.  The combined decrease in neutrophil emigration and 
oxidized phospholipids is a likely explanation for the decrease in lung injury in the setting of 
influenza infection.   
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To confirm the role of IL-17RA signaling and the role of neutrophils in the generation of 
oxidized phospholipids, we used a monoclonal antibody specific for Ly6G to deplete neutrophils 
during influenza infection.  Neutrophil depletion was observed in both the peripheral blood and 
BALF.  Importantly, this resulted in a decrease in oxidized phospholipids in the BALF, which 
therefore suggests that the decrease in neutrophils that we observed in the IL-17RA-/- mice was 
sufficient to explain the decrease in oxidized phospholipids in that model.  Additionally, this 
conferred a survival advantage among the anti-Ly6G-treated mice, further demonstrating the 
protective effect in decreasing oxidized phospholipids.  Interestingly, this is in apparent contrast 
to other reports that describe a detrimental effect to depletion of neutrophils (38, 341, 342).  This 
may be due to differences in viral strains used, or due to differences in antibody specificity, as 
the other reports have used anti-Gr1, which not only recognizes Ly6G but also Ly6C, resulting in 
depletion of other cell subsets in addition to neutrophils. 
We have also examined a non-infectious model of acute lung injury-acid aspiration- to 
determine if the role of IL-17 signaling is common to different causes of lung injury.  Again, in 
this model IL-17RA was required for neutrophil recruitment, generation of oxidized 
phospholipids, and ultimately, higher levels of lung injury.  The specific role of neutrophils in 
the generation of oxidized phospholipids in this model was shown using anti-Gr1 depletion of 
neutrophils.  Taken together these data strongly implicate IL-17RA signaling in neutrophil 
recruitment and the generation of oxidized phospholipids in both influenza and acid aspiration.  
Moreover, in the setting of influenza infection, lung injury due to IL-17RA signaling is 
independent of TNF-α or IL-6.   These data support the potential therapeutic manipulation of IL-
17 or IL-17RA in acute lung injury.   
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The role for oxidative damage in lung injury is supported by another report (370) 
examining production of reactive oxygen species in influenza-challenged mice.  Similar to our 
model, Cybb tm1 mice (lacking the gp91phox subunit of phagocyte NADPH oxidase) 
demonstrate less lung injury than wild-type control mice as measured by both total protein and 
LDH in the BALF following influenza challenge.  Additionally, these mice exhibited better lung 
function by whole body plethysmography.  However, in contrast to our model, these mice 
exhibited increased weight loss and airway cellularity, as well as improved viral clearance, 
suggesting a role for ROS in regulating the immune response.  It is possible, then, that in that 
model, the decrease in lung injury may not only be due to a direct role for ROS in causing injury, 
but also due to more efficient viral clearance (370). 
Other studies have also suggested roles for ROS in regulating lung inflammation.  Mice 
lacking the p47phox gene, which also leads to a non-functional NADPH oxidase, produce fewer 
ROS in response to intratracheal administration of lipopolysaccharide (371) or hydrochloric acid.  
However, in response to acid aspiration, these mice have more neutrophils recruited to the 
airway and fewer macrophages, leading to an increase in lung injury (372).  This suggests a 
beneficial role for ROS in driving a less injurious monocytic response and limiting a more 
damaging neutrophilic response.  However, in our IL-17RA knockout model, this is less of a 
concern due to the fact that the neutrophil response is already attenuated. 
If the signaling of oxidized phospholipids via TLR-4 were the only mechanism behind 
our phenotype, one would expect that TLR-4 null mice would be protected from lung injury in 
the setting of influenza challenge.  While that question has not been explicitly examined, 
multiple groups have demonstrated that TLR-4 knockout mice have no differences in viral 
clearance compared to wild-type controls, nor do they exhibit any deficits in the recruitment of 
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inflammatory cells to the airway or production of proinflammatory cytokines (373, 374).  
Further, no differences in histopathology are noted (374), suggesting that these mice have just as 
much inflammation as the wild-type controls, even though oxidized phospholipids signaling 
through TLR-4 would presumably be ablated.  This would seem to suggest that in our IL-17RA 
knockout model, while it is apparent that a decrease in oxidized phospholipids contributes to the 
phenotype we observe, it may not be the only explanation. 
Aside from any role a reduction in ROS might have in regulating the inflammatory 
response in the lung, there may be additional mechanisms that were not explored here.  In 
addition to the production of ROS, which in turn result in the production of oxidized 
phospholipids and direct oxidative damage to cells, neutrophils are also an important source of 
proteases that are capable of degrading the extracellular matrix of the lung and thereby 
contributing to lung injury (58, 63).  Interestingly, production of proteases by the neutrophil may 
contribute to a “feed-forward” loop to recruit more neutrophils.  Elastase production can result in 
the cleavage of CXCR1 on the surface of neutrophils, and the resulting CXCR1 fragment 
stimulates further IL-8/MIP-2 production, driving neutrophil recruitment (375).  Therefore, by 
reducing neutrophils in the IL-17RA knockout mice, we are also reducing the effects of 
neutrophil-derived proteases, which may help to lessen the lung injury. 
CCR2-mediated recruitment of monocytes has been shown to contribute to TRAIL-
mediated epithelial cell death following influenza, and lung injury is reduced in mice lacking 
CCR2 (376). In addition to the differences in neutrophils, we also saw a trend towards fewer 
macrophages in the BALF, supported by a trend towards lower MCP-1 in the IL-17RA knockout 
mice (data not shown); therefore, there may be neutrophil-independent mechanisms that are also 
contributing to the phenotype we describe here. 
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Somewhat related, it has also previously been shown that TLR3-deficient mice have a 
similar phenotype with decreased inflammation, decreased weight loss, and decreased mortality 
despite slightly higher viral titers (111).  Similar to oxidized phospholipids signaling through 
TLR4, TLR3 signals through TRIF and not MyD88 (110).  This provides further evidence that 
TRIF signaling may play a key role in ALI.  
IL-17 signaling has not been extensively studied in viral models, despite the fact that the 
cytokine has been detected in the settting of viral infection (302, 303).  A recent report has 
described the generation of IL-17+ CD8+ T cells- termed Tc17 cells- in response to influenza.  
These cells, when generated in vivo and transferred to mice prior to influenza challenge were 
protective, though these cells lacked granzyme B and perforin.  Additionally, in apparent contrast 
to our study, antibody neutralization of IL-17 reduced protection from heterosubtypical challenge 
(160).  This may be due to a role for IL-17 in the memory response, something that we do not 
examine in the present study.    
While our mouse model of influenza A/PR/8 infection is well-characterized, it is 
important to note that it may differ from infection with other strains or from human influenza.  
However, our observations are similar to those made by others in a corneal HSV-1 model (304), 
in which it was shown that IL-17RA knockout mice have decreased neutrophil infiltration that 
correlated with a decrease in corneal opacity- suggesting less tissue damage- at 24 hours post-
challenge.  In contrast to our model, this effect was transient, with the IL-17RA knockouts 
having similar levels of neutrophils and corneal pathology by 4 dpi.  These data seem to suggest 
that therapeutic modulation of IL-17 signaling may be beneficial not only in ALI, but also in 
treating immunopathology associated with viral infections of other organs. 
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3.0 TIMECOURSE AND CELLULAR SOURCE OF IL-17 PRODUCTION IN 
RESPONSE TO INFLUENZA CHALLENGE 
 
 
3.1 ABSTRACT 
 
Interleukin-17 is a cytokine produced in response to a variety of infectious (and non-infectious) 
agents, and is critical in regulating the host neutrophil response through upregulation of 
granulopoetic factors and chemokines.  Production of IL-17 has been described by several cell 
types, including CD4+ and CD8+ T cells, γδ T cells, and NK1.1neg invariant NKT cells.  We 
have previously shown that mice lacking IL-17RA are protected from lung injury during 
influenza challenge, but the timecourse and cellular source(s) of IL-17 production in this model 
remain undescribed.  Here we demonstrate that IL-17 mRNA and protein is detectable in the 
lung as early as 48 hours post-challenge and persists throughout the course of infection.  The cell 
population responsible for IL-17 is small but detectable, and seems to be predominated by γδ T 
cells.  We therefore conclude that γδ T cells are a critical source of IL-17 in response to influenza 
challenge. 
 
 
3.2 INTRODUCTION 
 
Multiple studies have demonstrated that IL-17 is produced in response to a variety of infectious 
pathogens.  This includes both bacterial pathogens such as E. coli, (223) L. monocytogenes (300, 
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301), K. pneumoniae (273), and M. pneumoniae (274) as well as fungal pathogens, including P. 
carinii (279), C. albicans (280), A. fumigatus, and C. neoformans (283).  IL-17 has also been 
detected in the setting of viral infections such as Human Immunodeficiency Virus (HIV) (302) 
and Herpes Simplex Virus (HSV) (304).  Further, we have already demonstrated that mice 
lacking IL-17 signaling are protected from the lung immunopathology associated with severe 
influenza infection (see section 2.0), implying that IL-17 is also made in response to this virus.  
However, the timecourse and cellular source of IL-17 in this model remain incompletely 
described. 
Multiple cell types have been demonstrated to be capable of producing IL-17.  Perhaps 
the best described are CD4+ effector T cells.  CD4+ T cells capable of producing IL-17 comprise 
a specific subset of cells, termed Th17 cells.  In the mouse model, polarization of CD4+ T cells 
towards a Th17 phenotype is dependent upon IL-6, TGF-β, and IL-1β (229−231).  IL-23 is also 
involved, playing a role in the expansion and maintenance of the Th17 population (236, 237). An 
alternative pathway of Th17 polarization, dependent upon IL-21, has also been described (232, 
251). 
In addition to CD4+ T cells, CD8+ T cells have also been shown to be capable of IL-17 
production (160, 219).  A recent report by Hamada, et. al. describes a CD8+ T cell subset 
analogous to Th17 cells that is capable of producing IL-17, terming them Tc17 cells.  
Interestingly, these cells are present during influenza infection and are capable of providing 
protection when adoptively transferred 24 hours prior to influenza challenge (160). 
Several studies have also identified γδ T cells as a source of IL-17 (222, 223, 252, 297, 
300).  In an E. coli challenge model, γδ T cells in the peritoneal cavity are capable of producing 
IL-17 (297).  At least in vitro, the ability to produce IL-17 is enhanced by exogenous IL-23 
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(223).  Subsequent studies have demonstrated that these γδ T cells differentiate into IL-17 
producers while still in the thymus (222).  Further, others have demonstrated that γδ cells 
differentiate into IL-17 producers or IFN-γ producers during thymic selection, with antigen-naïve 
cells becoming IL-17 promoters and antigen-experienced cells becoming IFN-γ producers (252).  
Differentiating during thymic selection would allow these cells to rapidly produce IL-17 in 
response to antigenic stimulation once in the periphery. 
A recent report has also identified a distinct population of invariant NKT (iNKT) cells 
capable of producing IL-17 and driving neutrophilia in the lung.  These cells lack the NK1.1 
marker, but are stimulated by CD1d-bound α-galactosylceramide to produce IL-17.  In contrast, 
NK1.1 positive cells are poor producers of IL-17 (218). 
In addition to these cell populations, IL-17mRNA has been detected in neutrophils, 
though IL-17 protein secretion by these cells has not been demonstrated (224).  Another study 
has shown production of IL-17 by macrophages in the setting of allergic lung inflammation.  
Mediators released by mast cells upregulated IL-17 production by the macrophages, whereas IL-
10 inhibited IL-17 production (377). 
In the present study, we sought to identify when IL-17 was produced in response to 
influenza challenge, and what cells were producing it.  We show here that IL-17 is upregulated 
as early as two days post-infection, and is detectable throughout the first week of infection, at 
which point the mice succumb to the lethal infection.  Further, we demonstrate that the number 
of IL-17 producing cells is rather small, but still detectable.  This IL-17+ population is 
predominantly γδ T cells.  In support of this, mice lacking γδ T cells have a decrease in IL-17, 
suggesting that these cells are a critical source of IL-17A and F. 
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3.3 METHODS 
 
3.3.1 Animal Infections 
 
IL-17ra on a BALB/cJ background (350) and γδ knockout mice on the B6 background 
(378) have been previously described.  Wild-type controls included BALB/cJ, and C57BL6 
mice.  IL-17-IRES-GFP reporter mice used in these experiments have not been previously 
described.  Briefly, A BAC clone consisting of IL-17A genomic DNA derived from C57BL/6 
mice was purchased from BacPac (Oakland, CA). An 8-kb BamHI-MluI fragment comprising 
exons 1, 2 and 3 for IL-17A gene was cloned into pEasy-Flox vector adjacent to the thymidine 
kinase selection marker. The IRES-eGFP cassette was linked to a LoxP-flanked neomycin (Neo) 
selection marker to obtain the IRES-eGFP-Neo cassette. The targeting construct was generated 
by cloning the IRES-eGFP-Neo cassette into a SacII site between the translation stop codon 
(UGA) and the polyadenylation signal (A2UA3) of the IL17A gene.  The targeting construct was 
linearized by ClaI cleavage and subsequently electroporated into Bruce4 C57BL/6 ES cells. 
Transfected ES cells were selected in the presence of 300 μg/ml G418 and 1 μM ganciclovir. 
Drug resistant ES cell clones were screened for homologous recombination by PCR. To obtain 
chimeric mice, correctly targeted ES clones were injected into BALB/c blastocysts, which were 
then implanted into CD1 pseudopregnant foster mothers. Male chimeras were bred with 
C57BL/6 to screen for germ-line transmitted offspring. Germ-line transmitted mice were bred 
with germline Cre transgenic mice (Tet-Cre mice) to remove the neomycin gene. Mice bearing 
the targeted IL-17A allele were screened by PCR.   
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Mice were challenged intranasally with a lethal dose of influenza A/PR/8/34 (H1N1) in 
phosphate-buffered saline (PBS).  Following infection, mice were monitored daily for weight 
loss and signs of clinical illness (352).  Mice were sacrificed at indicated time points.  Control 
mice received equivalent volumes of PBS. 
 
3.3.2 Real time PCR 
 
RNA collected from the left lung was used as template to generate cDNA using iScript reagents 
and protocol (BioRad).  cDNA was then used in fast real-time PCR using the Applied 
Biosystems 7900HT.  Reaction conditions were 95° Celsius for 1 second and 60°  for 20 
seconds, repeated for 40 cycles, with a 20 second hot start at 95°.  Primer and probe sequences 
were as follows: IL-17A Forward- 5’-GCT CCA GAA GGC CCT CAG A-3’, IL-17A Reverse- 
5’-CTT TCC CTC CGC ATT GAC A-3’, IL-17A probe- 5’-ACC TCA ACC GTT CCA CGT 
CAC CCT G-3’, IL-17F Forward- 5’AGG GCA TTT CTG TCC CAC GTG AAT-3’, IL-17F 
Reverse- 5’-GCA TTG ATG CAG CCT GAG TGT CT-3’, IL-17R Probe- 5’-CAT GGG ATT 
ACA ACA TCA CTC GAG ACC C-3’.  18s RNA was used as a housekeeping gene with the 
following primer/probe sequences: Forward- 5’-GAT CCA TTG GAG GGC AAG TCT-3’, 
Reverse- 5’- GCA GCA ACT TTA ATA TAC GCT ATT GC-3’, Probe- 5’-TGC CAG CAG 
CCG CGG TAA TTC-3’.  Fold change in RNA levels was calculated using the ΔΔCT method. 
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3.3.3 IL-17A and IL-17F ELISA 
 
Right lungs were collected in 1mL of PBS at the time of euthanasia and homogenized using an 
electronic tissue homogenizer.  Cellular debris was centrifuged out at 12,000 x g for 10 minutes.  
Supernatants were collected and concentrations of IL-17A and IL-17F were measured by ELISA 
(R&D) according to manufacturer’s instructions. 
 
3.3.4 IL-17A ELISpot 
 
For ELISpot, the lungs of each animal were collected in PBS and dissected into 1mm pieces 
under sterile conditions.  They were then digested with collagenase and DNAse for 45 minutes at 
37° Celsius.  The digest was passed through a 40 μm filter, red blood cells were lysed, and cells 
were washed 3x with PBS.  Cells were plated at 1x105 cells per well on an IL-17A ELISpot plate 
(eBioscience) in DMEM and stimulated with 50 ng/mL PMA and 750 ng/mL ionomycin 
overnight.  Plate was developed according to manufacturer’s instructions. 
 
3.3.5 Intracellular Cytokine Staining 
 
Lungs were collected and digested as described in section 3.3.4.  Cells were plated at a 
concentration of 1-2x106 cells/well in a sterile 96-well round-bottom plate and stimulated 
overnight in DMEM with 50 ng/mL PMA and 750 ng/mL ionomycin at 37 degrees Celsius.  
Brefeldin A was added during the last 6 hours of incubation.  Cells were then washed and 
resuspended in PBS + 2% fetal bovine serum (FBS), and Fc receptors were blocked.  Cells were 
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then stained with fluorochrome-conjugated monoclonal antibodies for CD4, CD8, TCR β chain, 
TCR δ chain, and α-galcer-CD1 tetramer in the dark, on ice, for 30 minutes.  Following staining, 
cells were washed prior to fixation and permeabilization, which was performed using the Cell 
Fixation and Permeabilization Kit (Beckton, Dickinson and Company) according to 
manufacturer’s instructions.  Intracellular staining was performed with fluorochrome-conjugated 
monoclonal antibody directed towards IL-17A. 
 
 
 
3.4 RESULTS 
 
3.4.1 IL-17 is induced during influenza infection 
 
Among IL-17 family members, IL-17A and IL-17F share the greatest homology, and 
both are capable of signaling through IL-17RA, though IL-17F binds with a much lower affinity 
(254).  BALB/c mice were challenged with 100 pfu of influenza A/PR/8/34 (H1N1), and 
following challenge we were able to detect an increase in IL-17A (Figure 11A) and IL-17F 
(Figure 11B) mRNA in lung tissue compared to baseline as early as 2 days post-infection (dpi). 
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Figure 11: IL-17A and IL-17F are expressed in response to influenza.  Time course of IL-17A (A and 
C) and IL-17F (B and D) following influenza challenge.  mRNA was detected by quantitative real-time 
PCR.  Fold change in mRNA was calculated using the ΔΔCT method, is expressed relative to naïve 
levels, with all timepoints having a p value of <0.05 compared to naïve controls.  Protein levels were 
detected by ELISA, and all timepoints had a p value of <0.05 compared to naïve controls.  (E) The 
number of IL-17A-producing cells was quantified by ELISpot *p=0.016, **p=0.003.  
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This increase in mRNA remains detectable through 7 dpi.  We sought to confirm this increase in 
mRNA by measuring protein levels.  IL-17A (Figure 11C) and IL-17F (Figure 11D) were 
detectable by ELISA from 2 dpi through 7 dpi.  Beyond 7 dpi, there was significant mortality 
among BALB/c mice.  Thus, to avoid survival bias in data analysis, we chose to use an early 
time point- 2 dpi- and a late time point- 6 dpi- for our studies.  In order to gauge the number of 
cells producing IL-17, we performed an ELISpot on lung digests at 2 and 6 dpi.  We found that 
the population of IL-17A producing cells was relatively small, at 0.01-0.02% of the lung digest, 
and that the size of this population was not statistically different between the early and later 
timepoint (Figure 11E). 
 
3.4.2 γδ T cells as a Source of IL-17 
 
The detection of IL-17 as early as 2 days post-infection is important due to the fact that 
CD4+ and CD8+ T cells are typically not recruited to the lung until 4 dpi or later in response to 
influenza (379).  This implies that IL-17 production must also involve resident cells, including γδ 
T cells, as recruited CD4+ and CD8+ cells would not yet be in the lung.  Therefore, our efforts 
were aimed at identifying which cells are producing IL-17, with a focus on resident cell 
populations. 
As illustrated in Figure 11E, the size of the IL-17-producing cell population was 
relatively small.  Therefore, to identify what cells were producing IL-17, we chose to 
perform intracellular cytokine staining.  Cells were restimulated with PMA/ionomycin 
prior to staining.   In addition to staining for IL-17 intracellularly, we also co-stained for a 
variety of surface markers, including CD4, TCR δ chain, and TCR β chain.  Additionally, 
 88 
αβ T cells
CTRL Day 2 Day 6
0
10
20
30
%
 IL
-1
7+
 C
el
ls
CD4 T cells
CTRL Day 2 Day 6
0
5
10
15
%
 IL
-1
7+
 C
el
ls
γδ T cells
CTRL Day 2 Day 6
0
10
20
30
40
50
60
%
 IL
-1
7+
 C
el
ls
iNKT Cells
CTRL Day 2 Day 6
0
10
20
30
%
 IL
-1
7+
 C
el
ls
 
A. B. 
C. D. 
 
Figure 12: Majority of IL-17+ cells are γδ T cells.  Lung digests from naïve or influenza-infected mice 
were stimulated overnight with PMA/Ionomycin and used for intracellular cytokine staining.  Cells were 
analyzed by flow cytometry, gating on the IL-17+ population.  Surface markers stained include T cell-
receptor β chain (A), CD4 (B), or T cell-receptor δ chain (C).  iNKT cells were stained using tetramer 
containing α-gal-cer bound to CD1d (D).  
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Figure 13: IL-17-GFP is produced by γδ T cells.  Challenge of IL-17A-GFP reporter mice demonstrates 
that there is a population of IL-17+ cells that costain as gd T cells, and that this population grows from 2 
to 6 dpi.  In contrast, there are nearly no IL-17+ cells in the ab T cell population, and a small iNKT IL-17+ 
population at 6dpi, though the majority of IL-17+ cells do not stain as iNKT cells. 
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we used tetramer consisting of α-gal-cer bound to CD1d to identify iNKT cells.  Upon analysis, 
we gated on the IL-17+ population and analyzed the surface staining profile of these cells.  
Following this treatment, the IL-17-producing cells from naïve mice were approximately 20% 
iNKT cells, 10% γδ T cells, and 30% αβ T cells (Figure 12).  In mice challenged with influenza, 
the γδ+ IL-17+ population expanded to constitute approximately 30% of the IL-17+ cells by day 
2 and over 50% by day 6 (Figure 12C) while the αβ T cells made up a correspondingly 
decreasing percentage of the IL-17+ population (Figure 12A).  This indicates that γδ T cells are a 
major source of IL-17 in response to influenza. 
 One major weakness of intracellular cytokine staining is that it requires the use of 
PMA/ionomycin to restimulate the cells.  To avoid this, we also challenged IL-17A-GFP reporter 
mice with influenza, and analyzed the IL-17A-GFP+ population at 2 and 6 days post-infection.  
In doing so, we observed nearly no IL-17 expression in cells from naïve lungs, and nearly all IL-
17+ cells following influenza challenge stained as γδ T cells, further confirming these cells as the 
source of IL-17 in our model.  Further, the size of this population increases from 2 to 6 dpi, and 
there are essentially no IL-17+ αβ T cells at this later timepoint, suggesting that the γδ T cells 
continue to be the predominant source of IL-17 even after the expansion of CD4+ and CD8+ T 
cells in the lung (Figure 13).    
 
3.4.3 γδ T cell-Deficient Mice Have Decreases in IL-17 
 
Based on the fact that γδ T cells have been identified as a major source of IL-17 in other models, 
and the fact that γδ T cells made up an increasingly large percentage of IL-17+ cells in our 
influenza model, we hypothesized that mice lacking γδ T cells would have a deficit in IL-17 
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production following influenza challenge.  To test this hypothesis, we challenged TCR δ -/- 
mice, which have deficient γδ T cell receptor expression, with influenza.  We then examined 
both IL-17A and IL-17F production at 2 and 6 dpi, looking at mRNA by semi-quantitative real-
time PCR.  In contrast to the BALB/c mice examined in figure 11, the change in IL-17A and IL-
17F mRNA among B6 controls at 2 dpi is less than 10-fold compared to naïve mice.  However, 
despite that, we detect a significant decrease in IL-17F message in the γδ knockout mice as early 
as 2 dpi, and at 6 dpi, both IL-17A and IL-17F mRNA is significantly decreased (Figure 14).  
This data further confirms the role of γδ T cells as a major source of IL-17 in the lung following 
influenza challenge. 
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Figure 14: γδ T cell-deficient mice make less IL-17.   Challenge of γδ knockout mice results in lower levels 
of IL-17A and IL-17F message, expressed as fold change from naïve, at 6dpi.  *p=0.03, **p=0.02. 
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 3.5 DISCUSSION 
 
There is considerable interest in understanding the role of individual cytokines- including IL-17- 
in host defense against infectious pathogens.  IL-17 has been shown to play a role in host defense 
against several pulmonary pathogens (for a complete discussion, refer to section 1.3.4).  In 
response to influenza challenge, IL-17 appears to play a role in the immunopathology, 
specifically through the regulation of the neutrophil response and subsequent oxidative damage 
(section 2.0).  However, to fully understand the role IL-17 plays, it is important to understand the 
source of the IL-17 and when it is produced.  This is even more essential if one hopes to use IL-
17 neutralization as a therapeutic strategy in treating acute lung injury.  
Th17 cells, a subset of CD4+ T cells, are perhaps the most well-described producers of 
IL-17 (307, 309, 380-383).  However, in the influenza model, antigen-specific CD4+ T cells 
don’t appear in the lung until 4 dpi or later (379, 384).  Because we observed IL-17A (and IL-
17F) as early as 2 dpi (Figure 11), it is likely that there is another cellular source of these 
cytokines in the early part of the infection.  In other models, CD8+ T cells (160, 219), γδ T cells 
(223), iNKT cells (218), macrophages (377) and neutrophils(224) have all been shown to 
produce IL-17 (though in the case of neutrophils, only mRNA has been measured).  Of these, 
CD8+ T cells have similar kinetics to the CD4+ T cell response in that they do not arrive in the 
lung until at least 4 dpi (379).  We hypothesized, therefore, that the IL-17 being produced early 
in the infection must be from some resident population, possibly γδ T cells. ELISpot results 
demonstrated that the population of IL-17+ cells was very small (Figure 11).  Through 
intracellular cytokine staining, we were able to demonstrate that much of the influenza-induced 
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IL-17 production was due to γδ T cells (Figure 12), though contributions from other cellular 
sources should not be considered insignificant. 
To follow up the results of our intracellular staining, we also challenged IL-17A-GFP 
reporter mice with influenza.  The primary advantage to this system is that there is no need to 
restimulate the cells in vitro.  By restimulating in vitro, it is reasonable to believe that you may 
be activating some cells that are capable of producing IL-17 that are not actually producing the 
cytokine in vivo.  Use of the reporter mouse system eliminates this potential variable.  Our data 
in these reporter mice confirms what we saw by intracellular staining, namely that IL-17+ cells 
are mostly γδ T cells, not αβ T cells.  Further, challenge of γδ knockout mice demonstrated a 
decrease in IL-17A and IL-17F message, providing additional support for the claim that γδ T 
cells are the primary source of IL-17 following influenza challenge. 
While it was expected that γδ T cells would be the primary producer of IL-17 early in the 
infection, it is somewhat suprising that they remain the primary producer of IL-17 at 6 dpi, a 
timepoint by which CD4+ and CD8+ T cells are more prominent in the lung.  A report has 
demonstrated IL-17+ CD8+ T cells in the lung following influenza infection, but those cells do 
not seem to significantly expand until 7 dpi or later (160).  Therefore, it is possible that other cell 
types, including CD8+ and CD4+ T cells, contribute to IL-17 production later in the influenza 
model, but at timepoints beyond the first week of infection.  This makes it unlikely that the 
production of IL-17 by these sources is contributing to the phenotype described in Chapter 2 of 
this report, in which mice succumb to the infection prior to the peak of the CD4+ and CD8+ T 
cell responses. 
While knowledge of the cellular source of IL-17 is critical to gaining an understanding of 
how the cytokine affects the response to influenza, it is also important to recognize that cells 
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producing IL-17 also produce other inflammatory mediators, and therefore may not make 
optimal therapeutic targets.  Further, the production of IL-17 may be necessary for other aspects 
of host defense.  In the case of γδ T cells, it has been shown that γδ T cell deficient mice have 
immune defects that result in worse outcomes in response to bacterial infections and other 
neutrophil-dominated inflammatory responses (385, 386).  Further, γδ T cells may play a role in 
resolution of lung injury in the influenza model, as well as heterosubtypic immunity (164, 387).  
Because of this, it may be preferential to not target the cells producing IL-17, but rather IL-17 
itself and its downstream mediators in an effort to mitigate the immunopathology observed in 
response to influenza.    
 
 
3.6 ACKNOWLEDGEMENTS 
 
The author would like to acknowledge the assistance and technical expertise of Kong Chen, 
Ph.D. for help with intracellular cytokine staining.  Thanks also to the laboratory of Dr. Richard 
Flavell (Yale), particularly William O’Connor, Ph.D., for providing IL-17A reporter mice and 
assistance in working with that model. 
 95 
4.0  SUMMARY AND CONCLUSIONS 
 
In this dissertation, we have described our efforts to understand the role of IL-17 signaling in 
response to influenza infection.  A summary of our results is as follows: 
 
1. IL-17 is produced early following influenza challenge- as soon as 2 days post-infection- 
and expression continues throughout the infection.  Resident cell populations- most 
notably γδ T cells, are at least one source of the IL-17 early, as CD4+ and CD8+ T cells 
are not recruited to the lung until day 4 or later.  However, this does not rule out the 
possibility of CD4+ or CD8+ T cells contributing to the IL-17 response later in the 
infection.  Due to the lethality of our model, we did not evaluate time points beyond 6 
days post-infection.  Other reports have, however, demonstrated IL-17 production by 
both CD4 and CD8 T cells in sublethal infections. 
2. IL-17RA signaling plays a key role in neutrophil recruitment to the lung, and this 
neutrophil recruitment is responsible for increased immunopathology.  We demonstrate 
that IL-17RA knockout mice have far fewer neutrophils in the airway.  This is associated 
with decreased morbidity- as measured by weight loss and signs of clinical illness- and 
mortality.  Specifically, these IL-17RA-deficient mice display far less inflammation and 
lung damage. 
3. Loss of IL-17RA signaling had a minimal but measurable impact on viral clearance.  The 
knockout mice had higher levels of virus at 6 days post-infection than their wild-type 
counterparts.  However, these animals were ultimately able to clear the infection and 
survive. 
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4. Decreases in neutrophil recruitment resulted in decreases in oxidative damage.  As 
expected, mice lacking IL-17RA had less myeloperoxidase in the lung.  We were also 
able to detect lower levels of oxidized phospholipids in these animals.  Oxidized 
phospholipids are capable of serving as an endogenous signal through Toll-like Receptor 
(TLR) 4 to induce acute lung injury.  Therefore, this serves as a probable mechanism for 
why IL-17RA knockout mice are protected from lung injury.  We were further able to 
demonstrate, using monoclonal antibodies to deplete neutrophils, that the differences in 
neutrophil numbers were sufficient to explain the differences in oxidized phospholipids. 
5. Decreases in neutrophil recruitment and production of oxidized phospholipids were also 
detected in IL-17RA mice treated with hydrochloric acid in the airway, compared to 
wild-type controls.  Because our findings are similar in this model of aspiration 
pneumonia, it suggests that IL-17 may play a key role in acute lung injury in response to 
a variety of stimuli.  This suggests that IL-17 may be an important therapeutic target for 
the treatment of acute lung injury. 
 
Based upon the findings detailed in this report, we therefore conclude that IL-17, 
produced mainly by γδ T cells in response to both infectious (influenza) and non-infectious (acid 
aspiration) insults to the airway, plays a key role in the pathogenesis of acute lung injury.  This is 
due, at least in part, to the recruitment of neutrophils to the lung, production of reactive oxygen 
species, and accumulation of oxidized phospholipids in the airway.  Therefore, therapies aimed 
at blocking this pathway may be useful in the treatment of acute lung injury. 
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